0001360442 --12-31 false 2024 Q3 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 0001360442 2024-01-01 2024-09-30 0001360442 2024-09-30 0001360442 2024-12-31 0001360442 2023-12-31 0001360442 2024-07-01 2024-09-30 0001360442 2023-07-01 2023-09-30 0001360442 2023-01-01 2023-09-30 0001360442 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001360442 2022-12-31 0001360442 us-gaap:CommonStockMember 2022-12-31 0001360442 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001360442 fil:RestatedAccumulatedDeficitMember 2022-12-31 0001360442 fil:NonControllingInterestPrestocorpMember 2022-12-31 0001360442 2023-01-01 2023-03-31 0001360442 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001360442 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001360442 fil:RestatedAccumulatedDeficitMember 2023-01-01 2023-03-31 0001360442 fil:NonControllingInterestPrestocorpMember 2023-01-01 2023-03-31 0001360442 2023-03-31 0001360442 us-gaap:CommonStockMember 2023-03-31 0001360442 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001360442 fil:RestatedAccumulatedDeficitMember 2023-03-31 0001360442 fil:NonControllingInterestPrestocorpMember 2023-03-31 0001360442 2023-04-01 2023-06-30 0001360442 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001360442 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001360442 fil:RestatedAccumulatedDeficitMember 2023-04-01 2023-06-30 0001360442 fil:NonControllingInterestPrestocorpMember 2023-04-01 2023-06-30 0001360442 2023-06-30 0001360442 us-gaap:CommonStockMember 2023-06-30 0001360442 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001360442 fil:RestatedAccumulatedDeficitMember 2023-06-30 0001360442 fil:NonControllingInterestPrestocorpMember 2023-06-30 0001360442 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001360442 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001360442 fil:RestatedAccumulatedDeficitMember 2023-07-01 2023-09-30 0001360442 fil:NonControllingInterestPrestocorpMember 2023-07-01 2023-09-30 0001360442 2023-09-30 0001360442 us-gaap:CommonStockMember 2023-09-30 0001360442 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001360442 fil:RestatedAccumulatedDeficitMember 2023-09-30 0001360442 fil:NonControllingInterestPrestocorpMember 2023-09-30 0001360442 us-gaap:CommonStockMember 2023-12-31 0001360442 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001360442 fil:RestatedAccumulatedDeficitMember 2023-12-31 0001360442 fil:NonControllingInterestPrestocorpMember 2023-12-31 0001360442 2024-01-01 2024-03-31 0001360442 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001360442 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001360442 fil:RestatedAccumulatedDeficitMember 2024-01-01 2024-03-31 0001360442 fil:NonControllingInterestPrestocorpMember 2024-01-01 2024-03-31 0001360442 2024-03-31 0001360442 us-gaap:CommonStockMember 2024-03-31 0001360442 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001360442 fil:RestatedAccumulatedDeficitMember 2024-03-31 0001360442 fil:NonControllingInterestPrestocorpMember 2024-03-31 0001360442 2024-04-01 2024-06-30 0001360442 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001360442 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001360442 fil:RestatedAccumulatedDeficitMember 2024-04-01 2024-06-30 0001360442 fil:NonControllingInterestPrestocorpMember 2024-04-01 2024-06-30 0001360442 2024-06-30 0001360442 us-gaap:CommonStockMember 2024-06-30 0001360442 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001360442 fil:RestatedAccumulatedDeficitMember 2024-06-30 0001360442 fil:NonControllingInterestPrestocorpMember 2024-06-30 0001360442 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001360442 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001360442 fil:RestatedAccumulatedDeficitMember 2024-07-01 2024-09-30 0001360442 fil:NonControllingInterestPrestocorpMember 2024-07-01 2024-09-30 0001360442 us-gaap:CommonStockMember 2024-09-30 0001360442 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001360442 fil:RestatedAccumulatedDeficitMember 2024-09-30 0001360442 fil:NonControllingInterestPrestocorpMember 2024-09-30 0001360442 fil:CannabisSativaMemberus-gaap:InternetDomainNamesMember 2024-09-30 0001360442 fil:CannabisSativaMemberus-gaap:InternetDomainNamesMember 2023-12-31 0001360442 fil:PrestocorpMemberus-gaap:IntellectualPropertyMember 2024-09-30 0001360442 fil:PrestocorpMemberus-gaap:IntellectualPropertyMember 2023-12-31 0001360442 fil:KPALMemberfil:PatentsAndTrademarksMember 2024-09-30 0001360442 fil:KPALMemberfil:PatentsAndTrademarksMember 2023-12-31 0001360442 fil:PrestocorpMember 2017-08-01 2017-08-01 0001360442 fil:PrestocorpMember 2024-09-30 0001360442 fil:PrestocorpMember 2023-12-31 0001360442 fil:ChiefExecutiveOfficerAndDirectorMember 2024-01-01 2024-09-30 0001360442 fil:ChiefExecutiveOfficerAndDirectorMember 2023-01-01 2023-09-30 0001360442 fil:ChiefExecutiveOfficerAndDirectorMember 2024-09-30 0001360442 fil:ChiefExecutiveOfficerAndDirectorMember 2023-12-31 0001360442 fil:Director1Member 2023-01-01 2023-09-30 0001360442 fil:Director1Member 2024-09-30 0001360442 fil:Director1Member 2023-12-31 0001360442 fil:Director1Member 2024-01-01 2024-09-30 0001360442 fil:RelatedPartyNotePayableMember 2024-09-30 0001360442 fil:RelatedPartyNotePayableMember 2023-09-30 0001360442 fil:RelatedPartyNotePayableMember 2024-07-01 2024-09-30 0001360442 fil:RelatedPartyNotePayableMember 2023-07-01 2023-09-30 0001360442 fil:RelatedPartyNotePayableMember 2024-01-01 2024-09-30 0001360442 fil:RelatedPartyNotePayableMember 2023-01-01 2023-09-30 0001360442 fil:NewCompendiumShareholderMember 2024-09-30 0001360442 fil:StockPayable1Member 2024-09-30 0001360442 fil:NewCompendiumShareholderMember 2023-12-31 0001360442 fil:StockPayable1Member 2023-12-31 0001360442 fil:OtherAffiliates1Member 2023-12-31 0001360442 fil:MjHarvestIncMember 2023-12-31 0001360442 fil:MjHarvestIncMember 2024-09-30 0001360442 fil:RefgMember 2024-09-30 0001360442 fil:RefgMember 2023-12-31 0001360442 fil:RefgMember 2023-01-01 2023-01-31 0001360442 fil:CBDGMemberus-gaap:CommonStockMember 2021-01-01 2021-12-31 0001360442 fil:CBDGMemberus-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001360442 fil:CBDGMember 2021-12-31 0001360442 fil:CBDGMember 2021-01-01 2021-12-31 0001360442 fil:CBDGMember 2024-09-30 0001360442 fil:CBDGMember 2023-12-31 0001360442 fil:CBDGMember 2024-07-01 2024-09-30 0001360442 fil:CBDGMember 2023-07-01 2023-09-30 0001360442 fil:CBDGMember 2024-01-01 2024-09-30 0001360442 fil:CBDGMember 2023-01-01 2023-09-30 0001360442 fil:N2023AgreementMemberfil:Director1Member 2023-01-31 0001360442 fil:N2023AgreementMemberfil:Director1Member 2023-12-19 0001360442 fil:N2023AgreementMemberfil:Director1Member 2023-01-01 2023-12-31 0001360442 fil:N2023AgreementMemberfil:Director1Member 2023-12-31 0001360442 fil:N2023AgreementMemberfil:Director1Member 2024-09-30 0001360442 fil:QuickCapitalLlcMemberfil:N2023AgreementMember 2023-09-18 0001360442 fil:QuickCapitalLlcMemberfil:N2023AgreementMember 2023-09-18 2023-09-18 0001360442 fil:QuickCapitalLlcMemberfil:N2023AgreementMember 2024-06-26 0001360442 fil:QuickCapitalLlcMemberfil:N2023AgreementMember 2024-06-26 2024-06-26 0001360442 fil:QuickCapitalLlcMemberfil:N2023AgreementMember 2024-07-18 0001360442 fil:QuickCapitalLlcMemberfil:N2023AgreementMember 2024-07-18 2024-07-18 0001360442 fil:QuickCapitalLlcMemberfil:N2023AgreementMember 2024-09-09 2024-09-09 0001360442 fil:QuickCapitalLlcMemberfil:N2023AgreementMember 2024-09-09 0001360442 fil:QuickCapitalLlcMemberfil:N2023AgreementMember 2024-09-30 2024-09-30 0001360442 fil:QuickCapitalLlcMemberfil:N2023AgreementMember 2024-09-30 0001360442 fil:ColonialStockTransferCompanyIncMemberfil:N2023AgreementMember 2023-08-16 0001360442 fil:ColonialStockTransferCompanyIncMemberfil:N2023AgreementMember 2023-08-16 2023-08-16 0001360442 fil:N2024AgreementMemberfil:Director1Member 2024-01-15 0001360442 fil:N2024AgreementMemberfil:Director1Member 2024-01-15 2024-01-15 0001360442 fil:N2024AgreementMemberfil:Director1Member 2024-09-30 0001360442 fil:QuickCapitalLlcMemberfil:N2024AgreementMember 2024-05-22 0001360442 fil:QuickCapitalLlcMemberfil:N2024AgreementMember 2024-05-22 2024-05-22 0001360442 fil:QuickCapitalLlcMemberfil:N2024AgreementMember 2024-09-30 0001360442 fil:RelatedPartyNotePayableMemberus-gaap:CommonStockMember 2023-01-01 2023-09-30 0001360442 fil:Director1Member 2024-07-01 2024-09-30 0001360442 fil:QuickCapitalLlcMember 2024-06-26 0001360442 fil:QuickCapitalLlcMember 2024-07-01 2024-09-30 0001360442 us-gaap:PreferredStockMember 2024-01-01 2024-09-30 0001360442 2020-09-25 0001360442 2021-01-27

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

___________________

 

FORM 10-Q

___________________

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the quarterly period ended: September 30, 2024

 

or

 

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the transition period from: _____________ to _____________

 

Commission File Number: 000-53571

 

Dogecoin Cash, Inc.

Formerly Cannabis Sativa, Inc.

 

Nevada

 

20-1898270

(State or Other Jurisdiction

 

(I.R.S. Employer

of Incorporation)

 

Identification No.)

 

355 W. Mesquite Blvd. #C-70 Mesquite, Nevada 89027

(Address of Principal Executive Office) (Zip Code)

 

(702) 762-3123

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address, and former fiscal year, if changed since last report)

———————

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of each exchange on which registered.

None

 

 

 


1


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated Filer

Smaller reporting company

Emerging growth company

 

 

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

 

The number of shares of the issuer’s Common Stock outstanding as of December 31, 2024, is 137,066,141.

 


2


PART I—FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Attached after signature page.

 

Item 1C. Cybersecurity

 

We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data. We currently have security measures in place to protect our clients, customers, employees,‌ and vendor information and prevent data loss and other security breaches. We only use third party software for accounting, billing and payroll that has robust compliance and is actively involved in continuous assessment of risks from cybersecurity threats, including prevention, mitigation, detection, and remediation of cybersecurity incidents.

  

Our CEO is responsible for overseeing our business operations and is responsible for day-to-day assessment and confers weekly with subsidiary webmaster to understand any risks from cybersecurity threats, including the prevention, mitigation, detection, and remediation of cybersecurity incidents.

 

As our core operations are virtual, it is routine to undertake activities to prevent, detect, and minimize the effects of cybersecurity incidents, maintain business continuity, contingency, and have recovery plans for use in the event of a cybersecurity incident by the administering of local and cloud based back up of files and emails. We currently do not carry a cyber liability insurance policy but are evaluating whether to acquire one to mitigate any financial impact of a cybersecurity breach.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Certain statements in this Report constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, among others, uncertainties relating to general economic and business conditions; industry trends; changes in demand for our products and services; uncertainties relating to customer plans and commitments and the timing of orders received from customers; announcements or changes in our pricing policies or that of our competitors; unanticipated delays in the development, market acceptance or installation of our products and services; changes in government regulations; availability of management and other key personnel; availability, terms, and deployment of capital; relationships with third-party equipment suppliers; and worldwide political stability and economic growth. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.


3


 

Results of Operations

 

Three Months Ended September 30, 2024, compared with the Three Months Ended September 30, 2023

 

 

 

Three Months Ended

 

 

 

A

 

 

B

 

 

A-B

 

 

 

September 30,

 

 

September 30,

 

 

Change

 

 

Change %

 

2024

2023

REVENUE

 

$

189,121 

 

 

$

271,207 

 

 

$

(88,806)

 

 

 

(27)

%

Cost of revenues

 

 

70,249 

 

 

 

102,472 

 

 

 

(36,506)

 

 

 

(30)

%

Cost of sales % of total sales

 

 

37 

%

 

 

38 

%

 

 

 

 

 

 

(1)

%

Gross profit

 

 

118,872 

 

 

 

168,735 

 

 

 

(52,300)

 

 

 

(26)

%

Gross profit % of sales

 

 

63 

%

 

 

62 

%

 

 

 

 

 

 

 

EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Professional fees

 

 

114,456 

 

 

 

61,065 

 

 

 

53,391 

 

 

 

87

%

Depreciation and amortization

 

 

301 

 

 

 

37,989 

 

 

 

(37,688)

 

 

 

(99)

%

Wages and salaries

 

 

82,293 

 

 

 

143,935 

 

 

 

(61,642)

 

 

 

(43)

%

Advertising

 

 

996 

 

 

 

1,637 

 

 

 

(641)

 

 

 

(39)

%

General and administrative

 

 

102,673 

 

 

 

145,633 

 

 

 

(42,960)

 

 

 

(29)

%

Total expenses

 

 

300,719 

 

 

 

390,259 

 

 

 

(159,172)

 

 

 

(41)

%

NET LOSS FROM CONTINUING OPERATIONS

 

 

(181,847)

 

 

 

(221,524)

 

 

 

39,677 

 

 

 

(18)

%

 

Revenue for the three months ended September 30, 2024, decreased 27% compared to the three months ended September 30, 2023. Cost of revenues as a percentage of sales decreased 30% between the periods. The decrease in revenues is primarily a result of the significant increase in competition for market share in the cannabis tele-medicine industry. This decrease in the demand for our service continued during the third quarter of 2024.

 

Total operating expenses decreased in September 30, 2024 compared with 2023 which trended down as did revenue in the current period. Decreases in depreciation and amortization, wages and salaries


4


and general and administrative expenses. PrestoDoctor management salaries also decreased in the three months ended September 30, 2024.

 

Nine Months Ended September 30, 2024, compared with the Nine Months Ended September 30, 2023

 

 

 

Nine Months Ended

 

 

 

A

 

 

B

 

 

A-B

 

 

 

September 30,

 

 

September 30,

 

 

Change

 

 

Change %

 

2024

2023

REVENUE

 

$

648,643 

 

 

$

939,772 

 

 

$

(291,129)

 

 

 

(31)

%

Cost of revenues

 

 

253,369 

 

 

 

328,481 

 

 

 

(75,112)

 

 

 

(23)

%

Cost of sales % of total sales

 

 

39 

%

 

 

35 

%

 

 

 

 

 

 

6

%

Gross profit

 

 

395,274 

 

 

 

611,291 

 

 

 

(216,017)

 

 

 

(35)

%

Gross profit % of sales

 

 

61 

%

 

 

65 

%

 

 

 

 

 

 

 

EXPENSES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Professional fees

 

 

263,690 

 

 

 

222,963 

 

 

 

40,727 

 

 

 

18

%

Depreciation and amortization

 

 

3,028 

 

 

 

113,968 

 

 

 

(110,940)

 

 

 

(97)

%

Wages and salaries

 

 

293,373 

 

 

 

468,728 

 

 

 

(175,355)

 

 

 

(37)

%

Advertising

 

 

8,928 

 

 

 

9,113 

 

 

 

(185)

 

 

 

(2)

%

General and administrative

 

 

380,838 

 

 

 

435,221 

 

 

 

(54,383)

 

 

 

(12)

%

Total expenses

 

 

949,857 

 

 

 

1,249,993 

 

 

 

(300,136)

 

 

 

(24)

%

NET LOSS FROM CONTINUING OPERATIONS

 

 

(554,583)

 

 

 

(417,178)

 

 

 

84,119 

 

 

 

(13)

%

 

Revenue for the nine months ended September 30, 2024, decreased 31% compared to the nine months ended September 30, 2023. Cost of revenues as a percentage of sales decreased 23% between the periods. The decrease in revenues is primarily a result of the significant increase in competition for market share in the cannabis tele-medicine industry. This decrease in the demand for our service continued during the third quarter of 2024.

 

Total operating expenses decreased in September 30, 2024 compared with 2023 which trended down as did revenue in the current period. Decreases in depreciation and amortization, wages and salaries and general and administrative expenses. PrestoDoctor management salaries also decreased in the nine months ended September 30, 2024.

 


5


 

Liquidity and Capital Resources

 

Cash used in operating activities was $78,400 in the nine months ended September 30,2024. We ended the third quarter of 2024 with $41,352 in cash on hand.

 

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net losses of $854,454 and $995,109, respectively, for the nine months ended September 30, 2024, and 2023 and had an accumulated deficit of $82,895,826 as of September 30, 2024. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.

 

The amount of cash on hand the Company has does not provide sufficient liquidity to meet the immediate needs of our current operations.

 

Off Balance Sheet Arrangements

 

None

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Conclusions of Management Regarding Effectiveness of Disclosure Controls and Procedures

 

At the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operations of the Company’s disclosure controls and procedures (as defined in Rule 13a – 15(e) and Rule 15d – 15(e) under the Exchange Act). Based on that evaluation, the CEO and the CFO have concluded that as of the end of the period covered by this report, the Company’s disclosure controls and procedures were not effective as it was determined that there were material weaknesses affecting our disclosure controls and procedures.

 

Management of the Company believes that these material weaknesses are due to the small size of the company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting


6


professionals. As the Company grows, management expects to increase the number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.

 

Changes in Internal Control over Financial Reporting

 

There was no change in our internal control over financial reporting during the quarter ended June 30, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We are not a party to any material legal proceedings, and, to the best of our knowledge, no such legal proceedings have been threatened against us.

 

Item 1A. Risk Factors

 

Not required.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 


7


 

Item 6. Exhibits.

 

The following documents are included as exhibits to this report:

 

(a) Exhibits

 

Exhibit

Number

 

SEC

Reference

Number

 

Title of Document

 

Notes

 

 

 

 

 

 

 

3.1

 

3

 

Articles of Incorporation

 

(1)

3.2

 

3

 

Bylaws

 

(1)

31.1

 

31

 

Section 302 Certification of Principal Executive Officer

 

 

31.2

 

31

 

Section 302 Certification of Principal Financial Officer

 

 

32.1

 

32

 

Section 1350 Certification of Principal Executive Officer

 

 

32.2

 

32

 

Section 1350 Certification of Principal Financial Officer

 

 

101.INS

 

 

 

XBRL Instance Document

 

(2)

101.SCH

 

 

 

XBRL Taxonomy Extension Schema

 

(2)

101.CAL

 

 

 

XBRL Taxonomy Extension Calculation Linkbase

 

(2)

101.DEF

 

 

 

XBRL Taxonomy Extension Definition Linkbase

 

(2)

101.LAB

 

 

 

XBRL Taxonomy Extension Label Linkbase

 

(2)

101.PRE

 

 

 

XBRL Taxonomy Extension Presentation Linkbase

 

(2)

 

(1) Incorporated by reference to Exhibits 3.01 and 3.02 of the Company’s Registration Statement on Form 10 filed January 28, 2009.

(2) XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.  

 


8


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dogecoin Cash, Inc.

 

Date: December 31, 2024

 

By:  

/s/ David Tobias

 

 

David Tobias

Principal Executive Officer

Principal Financial Officer

 

 


9


 

DOGECOIN CASH, INC.

 

Contents

 

 

 

Page

 

FINANCIAL STATEMENTS - UNAUDITED – for the three and nine months ended September 30, 2024 and 2023:

 

 

 

 

Condensed consolidated balance sheets

 

FS-2

 

 

 

 

 

Condensed consolidated statements of operations

 

FS-3

 

 

 

 

 

Condensed consolidated statements of changes in stockholders’ equity

 

FS-4

 

 

 

 

 

Condensed consolidated statements of cash flows

 

FS-5

 

 

 

 

 

Notes to condensed consolidated financial statements

 

FS-6 through FS-17

 

 


FS-1


 

DOGECOIN CASH, INC.

 

 

 

 

 

 

 

CONDENSED CONSOLIDATED BALANCE SHEETS - UNAUDITED

 

 

 

 

 

September 30,

 

December 31,

2024

 

2023

ASSETS

 

 

 

Current Assets

 

 

 

Cash

$41,352  

 

$83,762  

Investment in equity securities, at fair value

18,000  

 

66,000  

Right of use asset

-  

 

10,232  

 

 

 

 

Total Current Assets

59,352  

 

159,994  

 

 

 

 

 

 

 

 

Advances to related party

76,305  

 

75,054  

Property and equipment, net

2,231  

 

2,436  

Intangible assets, net

4,436  

 

7,259  

Goodwill

1,775,811  

 

1,775,811  

 

 

 

 

Total Assets

$1,918,135  

 

$2,020,554  

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

Current Liabilities

 

 

 

Accounts payable and accrued expenses

$126,808  

 

$175,066  

Operating lease liability, current

-  

 

10,232  

Accrued interest - related parties

20,939  

 

20,130  

Fair value of convertible component in convertible loans

174,490  

 

-  

Convertible notes payable

220,743  

 

118,818  

Notes payable to related parties

206,911  

 

161,170  

 

 

 

 

Total Current Liabilities

749,891  

 

485,416  

 

 

 

 

Long-term liabilities

 

 

 

Stock payable

1,042,773  

 

777,747  

 

 

 

 

Total Liabilities

1,792,664  

 

1,263,163  

 

 

 

 

Commitments and contingencies (Notes 6 and 8)

 

 

 

 

 

 

 

Stockholders' Equity

 

 

 

Common stock $0.001 par value; 495,000,000 shares authorized; 110,030,284 and 88,814,037 shares issued and outstanding, respectively

110,030  

 

88,815  

Additional paid-in capital

81,593,515  

 

81,392,196  

Accumulated deficit

(82,895,826) 

 

(82,083,492) 

 

 

 

 

Total Cannabis Sativa, Inc. Stockholders' Deficit

(1,192,281) 

 

(602,481) 

 

 

 

 

Non-Controlling Interest

1,317,752  

 

1,359,872  

 

 

 

 

Total Stockholders' Equity

125,471  

 

757,391  

 

 

 

 

Total Liabilities and Stockholders' Equity

$1,918,135  

 

$2,020,554  

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


FS-2


 

DOGECOIN CASH, INC.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

September 30,

 

September 30,

 

 

 

2024

 

2023

 

2024

 

2023

 

 

 

 

 

 

 

 

 

 

Revenues

 

 

$189,121  

 

$271,207  

 

$648,643  

 

$939,772  

 

 

 

 

 

 

 

 

 

 

Cost of Revenues

 

 

70,249  

 

102,472  

 

253,369  

 

328,481  

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

118,872  

 

168,735  

 

395,274  

 

611,291  

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

Professional fees

 

 

114,456  

 

61,065  

 

263,690  

 

222,963  

Depreciation and amortization

 

 

301  

 

37,989  

 

3,028  

 

113,968  

Wages and salaries

 

 

82,293  

 

143,935  

 

293,373  

 

468,728  

Advertising

 

 

996  

 

1,637  

 

8,928  

 

9,113  

General and administrative

 

 

102,673  

 

145,633  

 

380,838  

 

435,221  

 

 

 

 

 

 

 

 

 

 

Total Operating Expenses

 

 

300,719  

 

390,259  

 

949,857  

 

1,249,993  

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(181,847) 

 

(221,524) 

 

(554,583) 

 

(638,702) 

 

 

 

 

 

 

 

 

 

 

Other (Income) and Expenses

 

 

 

 

 

 

 

 

 

Unrealized (gain) loss on investment

 

 

7,500  

 

(28,800) 

 

15,000  

 

185,083  

Employee Retention Credit

 

 

-  

 

(139,970) 

 

-  

 

(139,970) 

(Gain) loss on debt settlement

 

 

44,406  

 

88,591  

 

52,182  

 

99,118  

Loss on return of investment securities

 

 

-  

 

-  

 

33,000  

 

155,735  

Financial expense

 

 

7,357  

 

37,327  

 

199,689  

 

56,441  

 

 

 

 

 

 

 

 

 

 

Total Other (Income) Expenses, Net

 

 

59,263  

 

(42,852) 

 

299,871  

 

356,407  

 

 

 

 

 

 

 

 

 

 

Loss Before Income Taxes

 

 

(241,110) 

 

(178,672) 

 

(854,454) 

 

(995,109) 

 

 

 

 

 

 

 

 

 

 

Income Taxes

 

 

-  

 

-  

 

-  

 

-  

 

 

 

 

 

 

 

 

 

 

Net Loss for the Period

 

 

(241,110) 

 

(178,672) 

 

(854,454) 

 

(995,109) 

 

 

 

 

 

 

 

 

 

 

Income (loss) attributable to non-controlling interest - PrestoCorp

 

 

(4,879) 

 

49,076  

 

(42,121) 

 

88,047  

 

 

 

 

 

 

 

 

 

 

Net Loss for the Period Attributable To Dogecoin Cash, Inc.

 

 

$(236,231) 

 

$(227,748) 

 

$(812,333) 

 

$(1,083,156) 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss for the Period per Common Share: Basic & Diluted

 

$(0.00) 

 

$(0.00) 

 

$(0.01) 

 

$(0.02) 

 

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding:

 

 

 

 

 

 

 

 

 

Basic & Diluted

 

 

107,508,142  

 

52,119,640  

 

96,970,853  

 

48,676,647  

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


FS-3


DOGECOIN CASH, INC.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

 

 

 

 

 

 

 

 

Shares

 

Amount

 

Additional Paid-In Capital

 

Accumulated Deficit

 

Non-controlling Interest - Prestocorp

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - January 1, 2023

 

45,566,363 

 

$45,567 

 

$80,939,618 

 

$(80,603,069) 

 

$1,290,566  

 

 

$1,672,682  

Common stock issued - note payable conversion

 

320,513 

 

321 

 

25,316 

 

-  

 

-  

 

 

25,637  

Net loss for the period

 

-  

 

-  

 

-  

 

(522,922) 

 

22,821  

 

 

(500,101) 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - March 31, 2023

 

45,886,876 

 

45,888 

 

80,964,934 

 

(81,125,991) 

 

1,313,387  

 

 

1,198,218  

Common stock issued - note payable conversion

 

1,711,397 

 

1,711 

 

37,289 

 

-  

 

-  

 

 

39,000  

Common stock issued for services

 

2,450,000 

 

2,450 

 

85,750 

 

-  

 

-  

 

 

88,200  

Net loss for the period

 

-  

 

-  

 

-  

 

(332,486) 

 

16,150  

 

 

(316,336) 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - June 30, 2023

 

50,048,273 

 

50,049 

 

81,087,973 

 

(81,458,477) 

 

1,329,537  

 

 

1,009,082  

Common stock issued - note payable conversion

 

9,778,937 

 

9,779 

 

185,498 

 

-  

 

-  

 

 

195,277  

Net loss for the period

 

-  

 

-  

 

-  

 

(227,748) 

 

49,076  

 

 

(178,672) 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - September 30, 2023

 

59,827,210 

 

$59,828 

 

$81,273,471 

 

$(81,686,225) 

 

$1,378,613  

 

 

$1,025,687  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - January 1, 2024

 

88,814,037 

 

$88,815 

 

$81,392,196 

 

$(82,083,492) 

 

$1,359,872  

 

 

$757,391  

Net loss for the period

 

-  

 

-  

 

-  

 

(200,273) 

 

(22,295) 

 

 

(222,568) 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - March 31, 2024

 

88,814,037 

 

88,815 

 

81,392,196 

 

(82,283,765) 

 

1,337,577  

 

 

534,823  

Common stock issued - note payable conversion

 

2,580,159 

 

2,580 

 

25,993 

 

-  

 

-  

 

 

28,573  

Common stock issued for services in accounts payable

 

11,620,476 

 

11,620 

 

112,240 

 

-  

 

-  

 

 

123,860  

Net loss for the period

 

-  

 

-  

 

-  

 

(375,830) 

 

(14,946) 

 

 

(390,776) 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - June 30, 2024

 

103,014,672 

 

$103,015 

 

$81,530,429 

 

$(82,659,595) 

 

$1,322,631  

 

 

$296,480  

Common stock issued - note payable conversion

 

7,015,612 

 

7,015 

 

63,086 

 

-  

 

-  

 

 

70,101  

Net loss for the period

 

-  

 

-  

 

-  

 

(236,231) 

 

(4,879) 

 

 

(241,110) 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance - September 30, 2024

 

110,030,284 

 

$110,030 

 

$81,593,515 

 

$(82,895,826) 

 

$1,317,752  

 

 

$125,471  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


FS-4


DOGECOIN CASH, INC.

 

 

 

 

 

 

 

 

 

 

 

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - UNAUDITED

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the nine months ended September 30,

 

2024

 

 

2023

 

 

 

 

 

Cash Flows From Operating Activities:

 

 

 

Net loss for the period

 

$(854,454) 

 

 

$(995,109) 

Adjustments to reconcile net loss for the period to net cash used in operating activities:

 

 

 

 

 

Unrealized loss on investments

 

15,000  

 

 

185,083  

Interest expense - default on notes

 

-  

 

 

21,223  

Depreciation and amortization

 

3,028  

 

 

113,968  

Loss on debt settlement

 

52,182  

 

 

99,231  

Loss on return of investment securities

 

33,000  

 

 

155,735  

Stock issued for services

 

-  

 

 

88,200  

Stock payable for services

 

390,631  

 

 

319,701  

Note payable issued for services

 

42,500  

 

 

70,000  

Changes in Assets and Liabilities:

 

 

 

 

 

Accounts payable and accrued expenses

 

63,197  

 

 

(90,142) 

Fair value of convertible component in convertible loans

 

174,490  

 

 

-  

Accrued interest - related parties

 

2,026  

 

 

150  

Net Cash Used in Operating Activities

 

(78,400) 

 

 

(31,960) 

 

 

 

 

 

 

 

Cash Flows from Investing Activities:

 

 

 

 

 

Proceeds from sale of stock held for investment

 

-  

 

 

9,040  

Advances to related party

 

(1,250) 

 

 

(19,388) 

Net Cash Used in Investing Activities

 

(1,250) 

 

 

(10,348) 

 

 

 

 

 

 

 

Cash Flows from Financing Activities:

 

 

 

 

 

Proceeds from convertible note payable

 

30,000  

 

 

33,056  

Proceeds from related parties notes payable, net

 

7,240  

 

 

26,719  

Net Cash Provided by Financing Activities

 

37,240  

 

 

59,775  

 

 

 

 

 

 

 

NET CHANGE IN CASH

 

(42,410) 

 

 

17,467  

 

 

 

 

 

 

 

CASH AT BEGINNING OF PERIOD

 

83,762  

 

 

97,445  

 

 

 

 

 

 

 

CASH AT END OF PERIOD

 

$41,352  

 

 

$114,912  

 

 

 

 

 

 

 

Supplemental Disclosures of Non Cash Activities:

 

 

 

 

 

 Noncash investing and financing activities

 

 

 

 

 

 Shares issued in consideration of convertible notes and interest payable - related parties

 

$7,453  

 

 

$30,000  

 Shares issued in consideration of convertible notes payable

 

$91,221  

 

 

$160,236  

 Convertible note issued for payable

 

$86,022  

 

 

$-  

 Common stock issued for services in accounts payable

 

$123,860  

 

 

$-  

 

 

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 


FS-5


 

DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

 

1. Organization and Summary of Significant Accounting Policies

 

Nature of Business:

 

Dogecoin Cash, Inc. (the “Company,” “us”, “we” or “our”) was incorporated as Ultra Sun Corp. under the laws of Nevada in November 2004. On November 13, 2013, we changed our name to Cannabis Sativa, Inc. We operate through several subsidiaries including: 

 

·PrestoCorp, Inc. (“PrestoCorp”)  

·Wild Earth Naturals, Inc. (“Wild Earth”)  

·Kubby Patent and Licenses Limited Liability Company (“KPAL”)  

·Hi Brands, International, Inc. (“Hi Brands”)  

·Eden Holdings LLC (“Eden”).   

 

PrestoCorp is a 51% owned subsidiary. Wild Earth, KPAL, Hi Brands, and Eden are wholly owned subsidiaries. At September 30, 2024 and December 31, 2023, PrestoCorp is the sole operating subsidiary.

 

Our primary operations for the nine months ended September 30, 2024 were through PrestoCorp, which provides telemedicine online referral services for customers desiring medical marijuana cards in states where medical marijuana has been legalized. The Company is actively seeking new business opportunities for acquisition and is continually reviewing opportunities for product and brand development through our Wild Earth, Hi Brands, and KPAL subsidiaries.

 

Basis of Presentation

 

Operating results for the three and nine months ended September 30, 2024, may not be indicative of the results expected for the full year ending December 31, 2024. For further information, refer to the financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

 

The interim financial statements should be read in conjunction with audited financial statements and related footnotes set forth in our annual report filed on Form 10-K for the year ended December 31, 2023, as filed with the United States Securities and Exchange Commission on May 14, 2024.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of September 30, 2024, and its results of operations, cash flows, and changes in stockholders’ equity for the three and nine months ended September 30, 2024. The financial statements do not include all of the information and notes required by accounting principles generally accepted in the United States (‘GAAP”) for complete financial statements.

 

Principles of Consolidation:

 

The condensed consolidated financial statements include the accounts of Cannabis Sativa, Inc. (the “Company” or “CBDS”), and its wholly-owned subsidiaries and PrestoCorp, a 51% owned subsidiary. All significant inter-company balances have been eliminated in consolidation.


FS-6


DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

Going Concern:

 

The Company has an accumulated deficit of $82,895,826 at September 30, 2024, which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they are due.

 

Use of Estimates:

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, and the value attributed to stock-based awards.

 

Net Loss per Share:

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company. Potentially dilutive shares are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. For the nine months ended September 30, 2024 and December 31, 2023 the Company had -0- and 50,000 outstanding warrants, respectively, and -0- shares of convertible preferred stock, respectively, that would be dilutive to future periods net income if converted.

 

Recent Accounting Pronouncement:

 

Accounting Standards Updates Adopted

 

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The update is to address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The update is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and with early adoption permitted. Early adoption of this update had no impact on the Company’s consolidated financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.


FS-7


 

DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

 

2. Intangibles and Goodwill

 

The Company considers all intangibles to be definite-lived assets with lives of 5 to 10 years. Intangibles consisted of the following at September 30, 2024 and December 31, 2023:

 

 

September 30,

2024

 

December 31,

2023

CBDS.com website (Cannabis Sativa)

$13,999  

 

$13,999  

Intellectual Property Rights (PrestoCorp)

240,000  

 

240,000  

Patents and Trademarks (KPAL)

1,281,411  

 

1,281,411  

Total Intangibles

1,535,410  

 

1,535,410  

Less: Accumulated Amortization

(1,530,974) 

 

(1,528,151) 

Net Intangible Assets

$4,436  

 

$7,259  

 

Amortization expense for the three and nine months ended September 30, 2024 and 2023 was $233 (2023: $37,921) and $3,028 (2023: $113,763), respectively.

 

Amortization of intangibles through 2029 is: 

 

October 1, 2024 to September 30, 2025

 

$

932 

October 1, 2025 to September 30, 2026

 

 

932 

October 1, 2026 to September 30, 2027

 

 

932 

October 1, 2027 to September 30, 2028

 

 

932 

October 1, 2028 to September 30, 2029

 

 

711

 

Goodwill in the amount of $3,010,202 was recorded as part of the acquisition of PrestoCorp that occurred on August 1, 2017. Cumulative impairment of the PrestoCorp goodwill totals $1,234,391 as of September 30, 2024 and December 31, 2023. The balance of goodwill at September 30, 2024 and December 31, 2023 was $1,775,811.


FS-8


DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

 

3. Related Party Transactions

 

In addition to items disclosed in Notes 6, the Company had additional related party transactions during the nine months ended September 30, 2024 and 2023.

 

Historically, the Company has received funds from borrowings on notes payable and advances from related parties and officers of the Company to cover operating expenses. Related parties include the officers and directors of the Company and a significant shareholder holding in excess of 10% of the Company’s outstanding shares.

 

During the nine months ended September 30, 2024 and 2023, David Tobias, the Company’s chief executive officer and director, loaned $7,240 and $22,721, respectively to the Company for notes payable bearing interest at the rate of 5% per annum due on December 31, 2024. The note payable totaled $55,160 and $59,420 at September 30, 2024 and December 31, 2023, respectively.

 

During the nine months ended June 30, 2024, the Company and Cathy Carroll, director, entered into a note payable for $42,500 for compensation due her for services. Ms. Carroll’s note bears interest at 5% per annum and is due December 31, 2024. The note payable totaled $151,750 and $109,250 at September 30, 2024 and December 31, 2023, respectively.

 

The Company also has an outstanding loan in the amount of $4,000 to a director of the Company.  It accrues interest at 5% per annum. On May 22, 2024, the Company paid off this loan and the accrued interest with stock.  See Note 6. 

 

During the three and nine months ended September 30, 2024 and 2023, the Company recorded interest expense related to notes payable to related parties at the rates between 5% and 8% per annum in the amounts of $586 (2023: $4,559) and $2,026 (2023: $16,374), respectively.

 

The following tables reflect the related party payable balances.  

 

September 30, 2024

Related party payables

 

Accrued interest

 

Total

 

 

David Tobias, CEO & Director

$55,161 

 

$18,047 

 

$73,208 

New Compendium, greater than 10% Shareholder

- 

 

1,906 

 

1,906 

Stock payable – Directors & Officers

818,750 

 

- 

 

818,750 

Cathy Carroll, Director

151,750 

 

986 

 

152,736 

Totals

$1,025,661 

 

$20,939 

 

$1,046,600 

 


FS-9


 

DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

 

3. Related Party Transactions continued

December 31, 2023

Related party payables

 

Accrued interest

 

Total

 

 

David Tobias, CEO & Director

$47,920 

 

$13,779 

 

$61,699 

New Compendium, greater than 10% Shareholder

- 

 

1,906 

 

1,906 

Cathy Carroll, Director

109,250 

 

986 

 

110,236 

Stock payable – Directors & Officers

606,250 

 

- 

 

606,250 

Other Affiliates

4,000 

 

1,200 

 

5,200 

Totals

$767,420 

 

$17,871 

 

$785,291 

 

At September 30, 2024 and December 31, 2023, the Company has a balance due from MJ Harvest, Inc., with whom the Company plans to merge, of $75,054 (see Note 9). The amount is included in advances to related party on the condensed consolidated balance sheets. The funds were advanced to MJ Harvest, Inc. to cover operating expenses.

 

At September 30, 2024 and December 31, 2023, the Company has a balance due from a director of $1,250 and $-0-, respectively. The amount is included in advances to related party on the condensed consolidated balance sheets. The funds were advanced to the director to cover upcoming consulting services.

 

The following tables reflect the related party transactions.  

 

Three Months Ended

September 30, 2024

Three Months Ended

September 30, 2023

Nine Months Ended

September 30, 2024

Nine Months Ended

September 30, 2023

Directors fees

$- 

$11,875 

$23,750 

$35,625 

Outside services

59,375 

59,375 

178,125 

178,125 

Management fee

2,500 

32,051 

29,787 

76,151 

Payroll expenses

- 

- 

38,896 

- 

 


FS-10


DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

 

4. Investments

 

At September 30, 2024 and December 31, 2023, the Company owns -0- shares of common stock of Medical Cannabis Payment Solutions (ticker: REFG). In January 2023, the Company sold all of its holdings in REFG for $9,041 and recognized a loss of $155,735.

 

In 2021, the Company received 1,500,000 shares of common stock and 1,500,000 shares of preferred stock of THC Pharmaceuticals Inc. (ticker: CBDG). The CBDG shares were received as consideration for the sale of the Company’s majority interest in iBud and GKMP in the year ended December 31, 2021. On the date of sale, the shares were valued at fair value which was $0.20 per share or $600,000 in the aggregate. The Company’s Chief Executive Officer and Chairman of the Board, David Tobias is a Director of CBDG. On January 1, 2024, the preferred shares were returned to CBDG.

 

The Company’s investment in CBDG represents 15% of CBDG’s voting shares on a fully diluted basis which, coupled with Mr. Tobias’ position as a director and his individual investment in CBDG, results in the Company having significant influence over CBDG. The Company elected to account for its investment in CBDG at fair value because the Company does not intend to hold the investment for a long period of time and the shares are readily marketable. The fair value of the Company’s investment at September 30, 2024 and December 31, 2023 was $18,000 and $66,000 resulting in a unrealized (gain) loss of $7,500 (2023: ($28,800)) and $15,000 (2023: $185,083) for the change in fair value during the three and nine months ended September 30, 2024 and 2023, respectively. The returned preferred shares are accounted for as a loss on return of investment securities on the statement of operations for the nine months ended September 30, 2024 in the amount of $33,000

 

5. Convertible Notes Payable

 

On January 1, 2023, the Company entered into an agreement with Carolyn Merrill (“Carolyn”) whereby the Company issued a convertible note to Carolyn with a principal amount of $72,262. As stated in the January 1, 2023, agreement Ms Merrill’s contract compensation will also be added to the note for her services through March 31, 2023 in the amount of $25,000. On December 19, 2023, $11,500 of note payable was converted to 6,700,000 shares common stock which were valued at $36,800 resulting in a loss on conversion of $25,300. Note payable at December 31, 2023 was $85,762. The note bears interest at 8% and has a term of one year when payment of principal and interest is due and 12% thereafter. If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 30% discount. Both methods are calculated using the average of the lowest 3 closing prices during the 30 trading days preceding the request for conversion. 

 

The Company accounted for the note in accordance with ASC 470-20, Debt with conversion and other Options. As of September 30, 2024, the conversion feature was revalued at $27,083


FS-11


DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

 

5. Convertible Notes Payable - continued

On September 18, 2023, the Company entered into an agreement with Quick Capital, LLC whereby the Company issued a convertible note with a principal amount of $33,055. The maturity date is nine months after the issue date, accruing interest at 12% per annum and can be converted after 180 days from date of issue at a fixed rate of $0.01 per share. On June 26, 2024, Quick Capital converted $7,613 of note payable, $2,967 accrued interest and $1,420 fees for a total of $12,000 into 1,200,000 shares common stock.  The market value on June 26, 2024 was $0.0176 or a market value of $21,120 which gave rise to a loss on conversion of $9,120. On July 18, 2024, Quick Capital converted $20,768 of note payable, $176 accrued interest and $1,457 fees for a total of $22,400 into 5,104,831 shares common stock.  The market value on July 18, 2024 was $0.011 or a market value of $56,153 which gave rise to a loss on conversion of $35,209.  On September 9, 2024, Quick Capital converted $4,675 of note payable, $78 accrued interest and $1,457 fees for a total of $6,210 into 1,910,781 shares common stock.  The market value on September 30, 2024 was $0.0073 or a market value of $13,949 which gave rise to a loss on conversion of $7,739.

 

The Company accounted for the note in accordance with ASC 470-20, Debt with conversion and other Options. As of September 30, 2024, the conversion feature was revalued at $103.

 

On August 16, 2023, the Company entered into an agreement with Colonial Stock Transfer Company, Inc., (“CSTC”) whereby the Company issued a convertible note to CSTC with a principal amount of $11,020. The note bears interest at 10% and has a term of one year when payment of principal and interest is due. If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 25% discount. The conversion methods are calculated using the lowest closing prices during the 25 trading days preceding the request for conversion.

 

On January 15, 2024, the Company entered into an agreement with Carolyn Merrill (“Carolyn”) whereby the Company issued a convertible note to Carolyn with a principal amount of $75,000. The note bears interest at 5% and has a term of one year when payment of principal and interest is due. If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 30% discount. Both methods are calculated using the average of the lowest 3 closing prices during the 30 trading days preceding the request for conversion.

 

The Company accounted for the note in accordance with ASC 470-20, Debt with conversion and other Options. As of June 30, 2024, the conversion feature was revalued at $147,304.

 

On May 22, 2024, the Company entered into an agreement with Quick Capital, LLC whereby the Company issued a convertible note with a principal amount of $33,333. The Company received $25,000 after loan costs of $5,000 and original issue discount of $3,333. The original issue discount is included in loss on debt settlement. The maturity date is nine months after the issue date, accruing interest at 12% per annum and can be converted after 180 days from date of issue at a fixed rate of $0.02 per share.


FS-12


DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

 

5. Convertible Notes Payable - continued

On August 5, 2024, the Company entered into an agreement with Colonial Stock Transfer Company, Inc., (“CSTC”) whereby the Company issued a convertible note to CSTC with a principal amount of $15,626. The note bears interest at 10% and has a term of one year when payment of principal and interest is due. Conversion will be with a 25% discount and will be calculated using the lowest closing price during the 25 trading days preceding the request for conversion.

 

The Company accounted for the note in accordance with ASC 470-20, Debt with conversion and other Options. As of September 30, 2024, the conversion feature was revalued at $0.

 

Interest expense for the three and nine months ended September 30, 2024 and 2023 was $2,640 (2023: $1,945) and $12,786 (2023: $13,761) respectively. Accrued interest payable is included in accounts payable and accrued expenses on the condensed consolidated balance sheet.

 

6. Stockholders’ Equity

 

Change in Authorized Shares

 

The Company increased the number of authorized common shares the Company is authorized to issue to 495,000,000 on August 8, 2022. This change in capital structure was approved without a meeting by the consent of the shareholders holding a majority of the common stock outstanding and Articles of Amendment were filed with the State of Nevada.  

 

Securities Issuances

 

During the nine months ended September 30, 2023, 11,810,847 shares of common stock were issued to convert $160,685 of a note payable to a non-related party.

 

During the nine months ended September 30, 2023, 2,450,000 shares of common stock were issued to pay bonuses in the amount of $88,200.

 

During the nine months ended September 30, 2024, 11,620,476 shares of common stock were issued to pay services that were included in accounts payable at December 2023 in the amount of $123,860.

 

During the nine months ended September 30, 2024, 1,380,159 shares of common stock were issued to convert $4,000 of a note payable and $1,217 of accrued interest to a related party. The note was converted at a discount of 30% at a average of the lowest closing prices for 30 days prior to January 29, 2024 which produced a loss on debt settlement of $2,236. See Note 3.

 

During the nine months ended September 30, 2024, 1,200,000 shares of common stock were issued to convert $7,613 of a note payable, $2,967 of accrued interest and $1,420 of fees. The note was converted at a flat rate of $0.01. Market value at date of conversion was $0.0176 which produced a loss on debt settlement of $9,120. See Note 5.


FS-13


DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

 

6. Stockholders’ Equity- continued

On July 18, 2024, Quick Capital converted $20,768 of note payable, $176 accrued interest and $1,457 fees for a total of $22,400 into 5,104,831 shares common stock.  The market value on July 18, 2024 was $0.011 or a market value of $56,153 which gave rise to a loss on conversion of $35,209.  

 

On September 9, 2024, Quick Capital converted $4,675 of note payable, $78 accrued interest and $1,457 fees for a total of $6,210 into 1,910,781 shares common stock.  The market value on September 30, 2024 was $0.0073 or a market value of $13,949 which gave rise to a loss on conversion of $7,739.

 

Stock payable at September 30, 2024 consists of 31,739,730 preferred shares and 20,992,665 restricted common shares owed to members of the board of directors and officers for directors’ fees and contract services.  These shares were valued at $818,750 based on the fair value of the Company’s common stock at the date of board authorization. An additional 21,247,612 common shares were owed to as non-related vendors at September 30, 2024 valued at $224,024 based on the fair value of the Company’s common stock at the date of board authorization. 

 

Stock Compensation Plans

 

2020 Stock Plan

 

On September 25, 2020, the Company adopted the Cannabis Sativa 2020 Stock Plan which authorized the Company to utilize common stock to compensate employees, officers, directors, and independent contractors for services provided to the Company. By resolution dated September 25, 2020, the Company authorized up to 1,000,000 shares of common stock to be issued pursuant to the 2020 Stock Plan. This amount was subsequently increased to 2,000,000 shares on January 27, 2021. At September 30, 2024 and December 31, 2023 44,425 shares were available for future issuance.

 

7. Commitments and Contingencies

 

Litigation.

 

In the ordinary course of business, we may face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject us to litigation. As of September 30, 2024, no claims are outstanding.


FS-14


DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

 

8. Proposed Merger with MJ Harvest, Inc.

 

On August 8, 2022, the Company entered into a Merger Agreement (the “Merger Agreement”) with MJ Harvest, Inc. (“MJHI”). Pursuant to the Merger Agreement, MJHI will merge with and into the Company and the Company will be the surviving corporation in the Merger.  The Merger is expected to be consummated once the shareholders of the Company and the shareholders of MJHI approve the Merger which management expects will be completed early in the second quarter of calendar year 2023.  The terms of the Merger Agreement are summarized below:

 

The name of the surviving company in the Merger will be Cannabis Sativa, Inc. 

 

Each share of MJHI common stock outstanding on the effective date of the Merger will be converted into 2.7 shares of CBDS Common Stock. 

 

The Merger is subject to majority approval of the shareholders of both MJHI and CBDS. 

 

The shareholders of MJHI and CBDS will have rights to dissent from the Merger, and, if the notice of dissent is properly given, the dissenting shareholders may be paid fair value for such dissented shares. 

 

The Board of Directors of the surviving company following the Merger is intended to consist of Patrick Bilton, Randy Lanier, Clinton Pyatt, and David Tobias. 

 

The Executive Officers of the Company following the Merger are intended to include Patrick Bilton - Chief Executive Officer, Clinton Pyatt - Chief Operating Officer. 

 

The Merger Agreement includes representations and warranties, covenants, and conditions for MJHI and CBDS as are customary for transactions of this nature. 

 

No brokerage fees are payable in connection with the Merger. 

 

If majority shareholder approval of the merger is not obtained, the Merger will not occur, and the Merger Agreement will be terminated. 

 

All costs and expenses in connection with the Merger transactions will be borne by CBDS, except that MJHI will be responsible for expenses of its own legal counsel and auditing costs. 

 

The merger was withdrawn with the SEC in August 2023. The Company and MJ Harvest are continuing discussions in hopes of completing this transaction. 


FS-15


 

DOGECOIN CASH, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended September 30, 2024 and 2023

 

9. Subsequent events

 

Entry into a Material Definitive Agreement: 

 

On November 13, 2024, the Board of Directors of Dogecoin Cash, Inc. (formerly Cannabis Sativa, Inc.) authorized the acquisition of 600,000,000 Dogecoin Cash (crypto symbol: DOG) tokens and the entity DogeSPAC, LLC, a Colorado-based entity, from DogeSPAC, LLC, a Puerto Rico company in exchange for 4,500,000 newly issued CBDS preferred shares. This acquisition supports Dogecoin Cash, Inc.’s strategic focus on integrating cryptocurrency solutions into its operational and transactional processes.

 

The Board of Directors authorized a change in the company’s name from Cannabis Sativa, Inc. to Dogecoin Cash, Inc. This change was officially filed and recorded with the state of Nevada on November 13, 2024, as part of the company’s strategic pivot towards digital currency and blockchain applications within its business model.

 

Disclaimer:

Dogecoin Cash, Inc., and the Dogecoin Cash (DOG) token, were inspired by the well-known cryptocurrency Dogecoin; however, Dogecoin Cash, Inc. is not affiliated with, endorsed by, or associated with Dogecoin or its development team.

 

Clarification on Identification:

To prevent any confusion between Dogecoin Cash, Inc. (CBDS), a corporate entity, and Dogecoin Cash (DOG), the cryptocurrency token, each has been assigned a unique CUSIP identifier. Dogecoin Cash, Inc. and its shares are registered with the symbol CBDS, while the Dogecoin Cash (DOG) tokens are identifiable solely within cryptocurrency markets.

 

Change of Auditor

 

On December 9, 2024, the Company’s Board of Directors approved the dismissal of Amitai CPA and engaged Asesoria Global as the Company’s independent registered public accounting firm. This change occurred subsequent to the reporting period ending 9/30/24.

 

There were no disagreements with Amitai CPA on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedures during the periods they audited or reviewed.

 

Designation of Preferred Shares

 

To support this transition, Dogecoin Cash, Inc. has declared a special dividend. Common shareholders of record as of November 25, 2024, will receive 1 preferred share for every 1,000 common shares held. This dividend reflects the Board’s commitment to provide value to shareholders in line with the company's new strategic direction.

 

Pursuant to Section 78.1955 of the Nevada Revised Statutes, the undersigned, David Tobias, being the duly authorized Chief Executive Officer of Dogecoin Cash, Inc, a corporation organized and existing under the laws of the State of Nevada does hereby certify that, pursuant to the authority conferred upon the Board of Directors of the Corporation by the Articles of Incorporation, as amended, and pursuant to the provisions of Section 78.1955 of the Nevada Revised Statutes, the Board of Directors, on November 13, duly adopted the following resolution designating a series of 5,000,000 shares of preferred stock as “Series A Preferred Stock”:

 


FS-16


 

1. Designation and Number of Shares

 

There is hereby designated a series of preferred stock of the Corporation as SERIES A Preferred Stock, consisting of 5,000,000 shares, par value $0.001 per share.

 

2. Dividends

 

Holders of SERIES A Preferred Stock shall be entitled to receive dividends at the rate of 1 common share per annum for each SERIES A Preferred share held on November 25 of each year. Dividends shall be NON CUMULATIVE.

 

3. Liquidation Preference

 

In the event of any liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, the holders of SERIES A Preferred Stock shall be entitled to receive, prior to any distribution to the holders of common stock or any other junior securities, an amount equal to $1 per share, plus any accrued and unpaid dividends.

 

4. Voting Rights

 

The holders of SERIES A Preferred Stock shall have the right to 1 vote for each preferred share held.

 

5. Conversion Rights

 

The holders of SERIES A Preferred Stock shall not have the right to convert their shares into common stock of the Corporation.

 

6. Redemption

 

The Corporation shall have the right to redeem shares of Series A Preferred Stock on or before October 25, 2034, by issuing 10 shares of common stock for each 1 share of Series A Preferred Stock issued and outstanding. Redemption shall be subject to providing prior written notice to the holders of Series A Preferred Stock in accordance with the Corporation’s bylaws, and any other applicable notice requirements, terms, and conditions set forth by the Corporation.

 


FS-17

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, David Tobias, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, of Cannabis Sativa, Inc., (the “Registrant”);

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

 

4.

The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant and have:

 

 

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 

 

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c)

evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 

 

d)

disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5.

The Registrant’s other certifying officer(s) and I have disclosed to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions);

 

 

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

 

 

 

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Date: December 31, 2024

By:

/s/ David Tobias

 

 

 

Principal Executive Officer

 

 

EXHIBIT 31.2

 

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, David Tobias, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, of Dogecoin Cash, Inc., (the “Registrant”);

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

 

4.

The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant and have:

 

 

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 

 

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c)

evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 

 

d)

disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5.

The Registrant’s other certifying officer(s) and I have disclosed to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions);

 

 

a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

 

 

 

b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Date: December 31, 2024

By:

/s/ David Tobias

 

 

 

David Tobias, Principal Financial Officer

 

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Cannabis Sativa, Inc. (the “Registrant”) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Commission on the date hereof (the “Quarterly Report”), I, David Tobias, Principal Executive Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Quarterly Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

Dated: December 31, 2024

 

 

 

 

 

/s/ David Tobias

 

 

David Tobias

Principal Executive Officer

 

 

 

 

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Dogecoin Cash, Inc. (the “Registrant”) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Commission on the date hereof (the “Quarterly Report”), I, David Tobias, Principal Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Quarterly Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

Dated: December 31, 2024

 

 

 

 

 

/s/ David Tobias

 

 

David Tobias

Principal Financial Officer

 

 

v3.24.4
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2024
Dec. 31, 2024
Details    
Registrant CIK 0001360442  
Fiscal Year End --12-31  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Securities Act File Number 000-53571  
Entity Registrant Name Dogecoin Cash, Inc.  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 20-1898270  
Entity Address, Address Line One 355 W. Mesquite Blvd.  
Entity Address, Address Line Two #C-70  
Entity Address, City or Town Mesquite  
Entity Address, State or Province NV  
Entity Address, Postal Zip Code 89027  
City Area Code 702  
Local Phone Number 762-3123  
Las Vegas Office Facilities Yes  
Las Vegas Office Facilities Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   137,066,141
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
v3.24.4
Condensed Consolidated Balance Sheets - Unaudited - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Current Assets    
Cash $ 41,352 $ 83,762
Investment in equity securities, at fair value 18,000 66,000
Right of use asset 0 10,232
Total Current Assets 59,352 159,994
Advances to related party 76,305 75,054
Property and equipment, net 2,231 2,436
Intangible assets, net 4,436 7,259
Goodwill 1,775,811 1,775,811
Total Assets 1,918,135 2,020,554
Current Liabilities    
Accounts payable and accrued expenses 126,808 175,066
Operating lease liability, current 0 10,232
Accrued interest - related parties 20,939 20,130
Fair value of convertible component in convertible loans 174,490 0
Convertible notes payable 220,743 118,818
Notes payable to related parties 206,911 161,170
Total Current Liabilities 749,891 485,416
Long-term liabilities    
Stock payable 1,042,773 777,747
Total Liabilities 1,792,664 1,263,163
Stockholders' Equity    
Common shares 110,030 88,815
Additional paid-in capital 81,593,515 81,392,196
Accumulated deficit (82,895,826) (82,083,492)
Total Cannabis Sativa, Inc. Stockholders' Deficit (1,192,281) (602,481)
Non-Controlling Interest 1,317,752 1,359,872
Total Stockholders' Equity 125,471 757,391
Total Liabilities and Stockholders' Equity $ 1,918,135 $ 2,020,554
v3.24.4
Condensed Consolidated Balance Sheets - Unaudited - Parenthetical - $ / shares
Sep. 30, 2024
Dec. 31, 2023
Condensed Consolidated Balance Sheets - Unaudited    
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Common Stock, Shares Authorized 495,000,000 495,000,000
Common Stock, Shares, Issued 110,030,284 88,814,037
Common Stock, Shares, Outstanding 110,030,284 88,814,037
v3.24.4
Condensed Consolidated Statements of Operations - Unaudited - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Condensed Consolidated Statements of Operations - Unaudited        
Revenues $ 189,121 $ 271,207 $ 648,643 $ 939,772
Cost of Revenues 70,249 102,472 253,369 328,481
Gross Profit 118,872 168,735 395,274 611,291
Operating Expenses        
Professional fees 114,456 61,065 263,690 222,963
Depreciation and amortization 301 37,989 3,028 113,968
Wages and salaries 82,293 143,935 293,373 468,728
Advertising 996 1,637 8,928 9,113
General and administrative 102,673 145,633 380,838 435,221
Total Operating Expenses 300,719 390,259 949,857 1,249,993
Loss from Operations (181,847) (221,524) (554,583) (638,702)
Other Nonoperating Income (Expense)        
Unrealized (gain) loss on investment 7,500 (28,800) 15,000 185,083
Employee Retention Credit 0 (139,970) 0 (139,970)
(Gain) loss on debt settlement 44,406 88,591 52,182 99,118
Loss on return of investment securities 0 0 33,000 155,735
Financial expense 7,357 37,327 199,689 56,441
Total Other (Income) Expenses, Net 59,263 (42,852) 299,871 356,407
Loss Before Income Taxes (241,110) (178,672) (854,454) (995,109)
Income Taxes 0 0 0 0
Net Loss for the Period (241,110) (178,672) (854,454) (995,109)
Income (loss) attributable to non-controlling interest - PrestoCorp (4,879) 49,076 (42,121) 88,047
Net Loss for the Period Attributable To Dogecoin Cash, Inc $ (236,231) $ (227,748) $ (812,333) $ (1,083,156)
Net Loss for the Period per Common Share: Basic & Diluted $ (0) $ (0) $ (0.01) $ (0.02)
Weighted Average Common Shares Outstanding: Basic And Diluted 107,508,142 52,119,640 96,970,853 48,676,647
v3.24.4
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Common Stock
Additional Paid-in Capital
Restated Accumulated Deficit
Non-controlling Interest - Prestocorp
Total
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2022 $ 45,567 $ 80,939,618 $ (80,603,069) $ 1,290,566 $ 1,672,682
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 45,566,363        
Common stock issued - note payable conversion $ 321 25,316 0 0 25,637
Common stock issued - note payable conversion 320,513        
Net Loss for the Period $ 0 0 (522,922) 22,821 (500,101)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2023 $ 45,888 80,964,934 (81,125,991) 1,313,387 1,198,218
Shares, Outstanding, Ending Balance at Mar. 31, 2023 45,886,876        
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2022 $ 45,567 80,939,618 (80,603,069) 1,290,566 1,672,682
Shares, Outstanding, Beginning Balance at Dec. 31, 2022 45,566,363        
Net Loss for the Period         (995,109)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2023 $ 59,828 81,273,471 (81,686,225) 1,378,613 1,025,687
Shares, Outstanding, Ending Balance at Sep. 30, 2023 59,827,210        
Shares issued in consideration of convertible notes payable         160,236
Stock issued for services         88,200
Common stock issued for services in accounts payable         0
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 31, 2023 $ 45,888 80,964,934 (81,125,991) 1,313,387 1,198,218
Shares, Outstanding, Beginning Balance at Mar. 31, 2023 45,886,876        
Common stock issued - note payable conversion 1,711,397        
Net Loss for the Period $ 0 0 (332,486) 16,150 (316,336)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2023 $ 50,049 81,087,973 (81,458,477) 1,329,537 1,009,082
Shares, Outstanding, Ending Balance at Jun. 30, 2023 50,048,273        
Shares issued in consideration of convertible notes payable $ 1,711 37,289 0 0 39,000
Stock issued for services $ 2,450 85,750 0 0 88,200
Stock Issued During Period, Shares, Issued for Services 2,450,000        
Common stock issued - note payable conversion 9,778,937        
Net Loss for the Period $ 0 0 (227,748) 49,076 (178,672)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2023 $ 59,828 81,273,471 (81,686,225) 1,378,613 1,025,687
Shares, Outstanding, Ending Balance at Sep. 30, 2023 59,827,210        
Shares issued in consideration of convertible notes payable $ 9,779 185,498 0 0 195,277
Stock issued for services         88,200
Stock Issued During Period, Shares, Issued for Services 2,450,000        
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2023 $ 88,815 81,392,196 (82,083,492) 1,359,872 757,391
Shares, Outstanding, Beginning Balance at Dec. 31, 2023 88,814,037        
Net Loss for the Period $ 0 0 (200,273) (22,295) (222,568)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2024 $ 88,815 81,392,196 (82,283,765) 1,337,577 534,823
Shares, Outstanding, Ending Balance at Mar. 31, 2024 88,814,037        
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2023 $ 88,815 81,392,196 (82,083,492) 1,359,872 757,391
Shares, Outstanding, Beginning Balance at Dec. 31, 2023 88,814,037        
Common stock issued - note payable conversion 1,380,159        
Net Loss for the Period         (854,454)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2024 $ 110,030 81,593,515 (82,895,826) 1,317,752 125,471
Shares, Outstanding, Ending Balance at Sep. 30, 2024 110,030,284        
Shares issued in consideration of convertible notes payable         91,221
Stock issued for services         0
Common stock issued for services in accounts payable         123,860
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 31, 2024 $ 88,815 81,392,196 (82,283,765) 1,337,577 534,823
Shares, Outstanding, Beginning Balance at Mar. 31, 2024 88,814,037        
Common stock issued - note payable conversion 2,580,159        
Net Loss for the Period $ 0 0 (375,830) (14,946) (390,776)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2024 $ 103,015 81,530,429 (82,659,595) 1,322,631 296,480
Shares, Outstanding, Ending Balance at Jun. 30, 2024 103,014,672        
Shares issued in consideration of convertible notes payable $ 2,580 25,993 0 0 28,573
Common stock issued for services in accounts payable $ 11,620 112,240 0 0 123,860
Common stock issued for services in accounts payable - shares 11,620,476        
Common stock issued - note payable conversion 7,015,612        
Net Loss for the Period $ 0 0 (236,231) (4,879) (241,110)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2024 $ 110,030 81,593,515 (82,895,826) 1,317,752 125,471
Shares, Outstanding, Ending Balance at Sep. 30, 2024 110,030,284        
Shares issued in consideration of convertible notes payable $ 7,015 $ 63,086 $ 0 $ 0 70,101
Common stock issued for services in accounts payable         $ 123,860
Common stock issued for services in accounts payable - shares 11,620,476        
v3.24.4
Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Cash Flows From Operating Activities        
Net loss for the period     $ (854,454) $ (995,109)
Adjustments to reconcile net loss for the period to net cash used in operating activities:        
Unrealized (gain) loss on investment $ 7,500 $ (28,800) 15,000 185,083
Interest expense - default on notes     0 21,223
Depreciation and amortization 301 37,989 3,028 113,968
Loss on debt settlement     52,182 99,231
Loss on return of investment securities 0 0 33,000 155,735
Stock issued for services   88,200 0 88,200
Stock payable for services     390,631 319,701
Note payable issued for services     42,500 70,000
Changes in Assets and Liabilities        
Accounts payable and accrued expenses     63,197 (90,142)
Fair value of convertible component in convertible loans     174,490 0
Accrued interest - related parties     2,026 150
Net Cash Used in Operating Activities     (78,400) (31,960)
Cash Flows from Investing Activities        
Proceeds from sale of stock held for investment     0 9,040
Advances to related party     (1,250) (19,388)
Net Cash Used in Investing Activities     (1,250) (10,348)
Cash Flows from Financing Activities        
Proceeds from convertible note payable     30,000 33,056
Proceeds from related parties notes payable, net     7,240 26,719
Net Cash Provided by Financing Activities     37,240 59,775
NET CHANGE IN CASH     (42,410) 17,467
CASH AT BEGINNING OF PERIOD     83,762 97,445
CASH AT END OF PERIOD 41,352 114,912 41,352 114,912
Supplemental Disclosures of Non Cash Activities        
Shares issued in consideration of convertible notes and interest payable - related parties     7,453 30,000
Shares issued in consideration of convertible notes payable 70,101 $ 195,277 91,221 160,236
Convertible note issued for payable     86,022 0
Common stock issued for services in accounts payable $ 123,860   $ 123,860 $ 0
v3.24.4
1. Organization and Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2024
Notes  
1. Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

 

Nature of Business:

 

Dogecoin Cash, Inc. (the “Company,” “us”, “we” or “our”) was incorporated as Ultra Sun Corp. under the laws of Nevada in November 2004. On November 13, 2013, we changed our name to Cannabis Sativa, Inc. We operate through several subsidiaries including: 

 

·PrestoCorp, Inc. (“PrestoCorp”)  

·Wild Earth Naturals, Inc. (“Wild Earth”)  

·Kubby Patent and Licenses Limited Liability Company (“KPAL”)  

·Hi Brands, International, Inc. (“Hi Brands”)  

·Eden Holdings LLC (“Eden”).   

 

PrestoCorp is a 51% owned subsidiary. Wild Earth, KPAL, Hi Brands, and Eden are wholly owned subsidiaries. At September 30, 2024 and December 31, 2023, PrestoCorp is the sole operating subsidiary.

 

Our primary operations for the nine months ended September 30, 2024 were through PrestoCorp, which provides telemedicine online referral services for customers desiring medical marijuana cards in states where medical marijuana has been legalized. The Company is actively seeking new business opportunities for acquisition and is continually reviewing opportunities for product and brand development through our Wild Earth, Hi Brands, and KPAL subsidiaries.

 

Basis of Presentation

 

Operating results for the three and nine months ended September 30, 2024, may not be indicative of the results expected for the full year ending December 31, 2024. For further information, refer to the financial statements and notes thereto in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

 

The interim financial statements should be read in conjunction with audited financial statements and related footnotes set forth in our annual report filed on Form 10-K for the year ended December 31, 2023, as filed with the United States Securities and Exchange Commission on May 14, 2024.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of September 30, 2024, and its results of operations, cash flows, and changes in stockholders’ equity for the three and nine months ended September 30, 2024. The financial statements do not include all of the information and notes required by accounting principles generally accepted in the United States (‘GAAP”) for complete financial statements.

 

Principles of Consolidation:

 

The condensed consolidated financial statements include the accounts of Cannabis Sativa, Inc. (the “Company” or “CBDS”), and its wholly-owned subsidiaries and PrestoCorp, a 51% owned subsidiary. All significant inter-company balances have been eliminated in consolidation.


FS-6


Going Concern:

 

The Company has an accumulated deficit of $82,895,826 at September 30, 2024, which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they are due.

 

Use of Estimates:

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, and the value attributed to stock-based awards.

 

Net Loss per Share:

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company. Potentially dilutive shares are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. For the nine months ended September 30, 2024 and December 31, 2023 the Company had -0- and 50,000 outstanding warrants, respectively, and -0- shares of convertible preferred stock, respectively, that would be dilutive to future periods net income if converted.

 

Recent Accounting Pronouncement:

 

Accounting Standards Updates Adopted

 

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The update is to address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The update is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and with early adoption permitted. Early adoption of this update had no impact on the Company’s consolidated financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

v3.24.4
2. Intangibles and Goodwill
9 Months Ended
Sep. 30, 2024
Notes  
2. Intangibles and Goodwill

2. Intangibles and Goodwill

 

The Company considers all intangibles to be definite-lived assets with lives of 5 to 10 years. Intangibles consisted of the following at September 30, 2024 and December 31, 2023:

 

 

September 30,

2024

 

December 31,

2023

CBDS.com website (Cannabis Sativa)

$13,999  

 

$13,999  

Intellectual Property Rights (PrestoCorp)

240,000  

 

240,000  

Patents and Trademarks (KPAL)

1,281,411  

 

1,281,411  

Total Intangibles

1,535,410  

 

1,535,410  

Less: Accumulated Amortization

(1,530,974) 

 

(1,528,151) 

Net Intangible Assets

$4,436  

 

$7,259  

 

Amortization expense for the three and nine months ended September 30, 2024 and 2023 was $233 (2023: $37,921) and $3,028 (2023: $113,763), respectively.

 

Amortization of intangibles through 2029 is: 

 

October 1, 2024 to September 30, 2025

 

$

932 

October 1, 2025 to September 30, 2026

 

 

932 

October 1, 2026 to September 30, 2027

 

 

932 

October 1, 2027 to September 30, 2028

 

 

932 

October 1, 2028 to September 30, 2029

 

 

711

 

Goodwill in the amount of $3,010,202 was recorded as part of the acquisition of PrestoCorp that occurred on August 1, 2017. Cumulative impairment of the PrestoCorp goodwill totals $1,234,391 as of September 30, 2024 and December 31, 2023. The balance of goodwill at September 30, 2024 and December 31, 2023 was $1,775,811.

v3.24.4
3. Related Party Transactions
9 Months Ended
Sep. 30, 2024
Notes  
3. Related Party Transactions

3. Related Party Transactions

 

In addition to items disclosed in Notes 6, the Company had additional related party transactions during the nine months ended September 30, 2024 and 2023.

 

Historically, the Company has received funds from borrowings on notes payable and advances from related parties and officers of the Company to cover operating expenses. Related parties include the officers and directors of the Company and a significant shareholder holding in excess of 10% of the Company’s outstanding shares.

 

During the nine months ended September 30, 2024 and 2023, David Tobias, the Company’s chief executive officer and director, loaned $7,240 and $22,721, respectively to the Company for notes payable bearing interest at the rate of 5% per annum due on December 31, 2024. The note payable totaled $55,160 and $59,420 at September 30, 2024 and December 31, 2023, respectively.

 

During the nine months ended June 30, 2024, the Company and Cathy Carroll, director, entered into a note payable for $42,500 for compensation due her for services. Ms. Carroll’s note bears interest at 5% per annum and is due December 31, 2024. The note payable totaled $151,750 and $109,250 at September 30, 2024 and December 31, 2023, respectively.

 

The Company also has an outstanding loan in the amount of $4,000 to a director of the Company.  It accrues interest at 5% per annum. On May 22, 2024, the Company paid off this loan and the accrued interest with stock.  See Note 6. 

 

During the three and nine months ended September 30, 2024 and 2023, the Company recorded interest expense related to notes payable to related parties at the rates between 5% and 8% per annum in the amounts of $586 (2023: $4,559) and $2,026 (2023: $16,374), respectively.

 

The following tables reflect the related party payable balances.  

 

September 30, 2024

Related party payables

 

Accrued interest

 

Total

 

 

David Tobias, CEO & Director

$55,161 

 

$18,047 

 

$73,208 

New Compendium, greater than 10% Shareholder

- 

 

1,906 

 

1,906 

Stock payable – Directors & Officers

818,750 

 

- 

 

818,750 

Cathy Carroll, Director

151,750 

 

986 

 

152,736 

Totals

$1,025,661 

 

$20,939 

 

$1,046,600 

 

 

December 31, 2023

Related party payables

 

Accrued interest

 

Total

 

 

David Tobias, CEO & Director

$47,920 

 

$13,779 

 

$61,699 

New Compendium, greater than 10% Shareholder

- 

 

1,906 

 

1,906 

Cathy Carroll, Director

109,250 

 

986 

 

110,236 

Stock payable – Directors & Officers

606,250 

 

- 

 

606,250 

Other Affiliates

4,000 

 

1,200 

 

5,200 

Totals

$767,420 

 

$17,871 

 

$785,291 

 

At September 30, 2024 and December 31, 2023, the Company has a balance due from MJ Harvest, Inc., with whom the Company plans to merge, of $75,054 (see Note 9). The amount is included in advances to related party on the condensed consolidated balance sheets. The funds were advanced to MJ Harvest, Inc. to cover operating expenses.

 

At September 30, 2024 and December 31, 2023, the Company has a balance due from a director of $1,250 and $-0-, respectively. The amount is included in advances to related party on the condensed consolidated balance sheets. The funds were advanced to the director to cover upcoming consulting services.

 

The following tables reflect the related party transactions.  

 

Three Months Ended

September 30, 2024

Three Months Ended

September 30, 2023

Nine Months Ended

September 30, 2024

Nine Months Ended

September 30, 2023

Directors fees

$- 

$11,875 

$23,750 

$35,625 

Outside services

59,375 

59,375 

178,125 

178,125 

Management fee

2,500 

32,051 

29,787 

76,151 

Payroll expenses

- 

- 

38,896 

- 

 

v3.24.4
4. Investments
9 Months Ended
Sep. 30, 2024
Notes  
4. Investments

4. Investments

 

At September 30, 2024 and December 31, 2023, the Company owns -0- shares of common stock of Medical Cannabis Payment Solutions (ticker: REFG). In January 2023, the Company sold all of its holdings in REFG for $9,041 and recognized a loss of $155,735.

 

In 2021, the Company received 1,500,000 shares of common stock and 1,500,000 shares of preferred stock of THC Pharmaceuticals Inc. (ticker: CBDG). The CBDG shares were received as consideration for the sale of the Company’s majority interest in iBud and GKMP in the year ended December 31, 2021. On the date of sale, the shares were valued at fair value which was $0.20 per share or $600,000 in the aggregate. The Company’s Chief Executive Officer and Chairman of the Board, David Tobias is a Director of CBDG. On January 1, 2024, the preferred shares were returned to CBDG.

 

The Company’s investment in CBDG represents 15% of CBDG’s voting shares on a fully diluted basis which, coupled with Mr. Tobias’ position as a director and his individual investment in CBDG, results in the Company having significant influence over CBDG. The Company elected to account for its investment in CBDG at fair value because the Company does not intend to hold the investment for a long period of time and the shares are readily marketable. The fair value of the Company’s investment at September 30, 2024 and December 31, 2023 was $18,000 and $66,000 resulting in a unrealized (gain) loss of $7,500 (2023: ($28,800)) and $15,000 (2023: $185,083) for the change in fair value during the three and nine months ended September 30, 2024 and 2023, respectively. The returned preferred shares are accounted for as a loss on return of investment securities on the statement of operations for the nine months ended September 30, 2024 in the amount of $33,000. 

v3.24.4
5. Convertible Notes Payable
9 Months Ended
Sep. 30, 2024
Notes  
5. Convertible Notes Payable

5. Convertible Notes Payable

 

On January 1, 2023, the Company entered into an agreement with Carolyn Merrill (“Carolyn”) whereby the Company issued a convertible note to Carolyn with a principal amount of $72,262. As stated in the January 1, 2023, agreement Ms Merrill’s contract compensation will also be added to the note for her services through March 31, 2023 in the amount of $25,000. On December 19, 2023, $11,500 of note payable was converted to 6,700,000 shares common stock which were valued at $36,800 resulting in a loss on conversion of $25,300. Note payable at December 31, 2023 was $85,762. The note bears interest at 8% and has a term of one year when payment of principal and interest is due and 12% thereafter. If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 30% discount. Both methods are calculated using the average of the lowest 3 closing prices during the 30 trading days preceding the request for conversion. 

 

The Company accounted for the note in accordance with ASC 470-20, Debt with conversion and other Options. As of September 30, 2024, the conversion feature was revalued at $27,083. 


FS-11


On September 18, 2023, the Company entered into an agreement with Quick Capital, LLC whereby the Company issued a convertible note with a principal amount of $33,055. The maturity date is nine months after the issue date, accruing interest at 12% per annum and can be converted after 180 days from date of issue at a fixed rate of $0.01 per share. On June 26, 2024, Quick Capital converted $7,613 of note payable, $2,967 accrued interest and $1,420 fees for a total of $12,000 into 1,200,000 shares common stock.  The market value on June 26, 2024 was $0.0176 or a market value of $21,120 which gave rise to a loss on conversion of $9,120. On July 18, 2024, Quick Capital converted $20,768 of note payable, $176 accrued interest and $1,457 fees for a total of $22,400 into 5,104,831 shares common stock.  The market value on July 18, 2024 was $0.011 or a market value of $56,153 which gave rise to a loss on conversion of $35,209.  On September 9, 2024, Quick Capital converted $4,675 of note payable, $78 accrued interest and $1,457 fees for a total of $6,210 into 1,910,781 shares common stock.  The market value on September 30, 2024 was $0.0073 or a market value of $13,949 which gave rise to a loss on conversion of $7,739.

 

The Company accounted for the note in accordance with ASC 470-20, Debt with conversion and other Options. As of September 30, 2024, the conversion feature was revalued at $103.

 

On August 16, 2023, the Company entered into an agreement with Colonial Stock Transfer Company, Inc., (“CSTC”) whereby the Company issued a convertible note to CSTC with a principal amount of $11,020. The note bears interest at 10% and has a term of one year when payment of principal and interest is due. If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 25% discount. The conversion methods are calculated using the lowest closing prices during the 25 trading days preceding the request for conversion.

 

On January 15, 2024, the Company entered into an agreement with Carolyn Merrill (“Carolyn”) whereby the Company issued a convertible note to Carolyn with a principal amount of $75,000. The note bears interest at 5% and has a term of one year when payment of principal and interest is due. If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 30% discount. Both methods are calculated using the average of the lowest 3 closing prices during the 30 trading days preceding the request for conversion.

 

The Company accounted for the note in accordance with ASC 470-20, Debt with conversion and other Options. As of June 30, 2024, the conversion feature was revalued at $147,304.

 

On May 22, 2024, the Company entered into an agreement with Quick Capital, LLC whereby the Company issued a convertible note with a principal amount of $33,333. The Company received $25,000 after loan costs of $5,000 and original issue discount of $3,333. The original issue discount is included in loss on debt settlement. The maturity date is nine months after the issue date, accruing interest at 12% per annum and can be converted after 180 days from date of issue at a fixed rate of $0.02 per share.


FS-12


On August 5, 2024, the Company entered into an agreement with Colonial Stock Transfer Company, Inc., (“CSTC”) whereby the Company issued a convertible note to CSTC with a principal amount of $15,626. The note bears interest at 10% and has a term of one year when payment of principal and interest is due. Conversion will be with a 25% discount and will be calculated using the lowest closing price during the 25 trading days preceding the request for conversion.

 

The Company accounted for the note in accordance with ASC 470-20, Debt with conversion and other Options. As of September 30, 2024, the conversion feature was revalued at $0.

 

Interest expense for the three and nine months ended September 30, 2024 and 2023 was $2,640 (2023: $1,945) and $12,786 (2023: $13,761) respectively. Accrued interest payable is included in accounts payable and accrued expenses on the condensed consolidated balance sheet.

v3.24.4
6. Stockholders' Equity
9 Months Ended
Sep. 30, 2024
Notes  
6. Stockholders' Equity

6. Stockholders’ Equity

 

Change in Authorized Shares

 

The Company increased the number of authorized common shares the Company is authorized to issue to 495,000,000 on August 8, 2022. This change in capital structure was approved without a meeting by the consent of the shareholders holding a majority of the common stock outstanding and Articles of Amendment were filed with the State of Nevada.  

 

Securities Issuances

 

During the nine months ended September 30, 2023, 11,810,847 shares of common stock were issued to convert $160,685 of a note payable to a non-related party.

 

During the nine months ended September 30, 2023, 2,450,000 shares of common stock were issued to pay bonuses in the amount of $88,200.

 

During the nine months ended September 30, 2024, 11,620,476 shares of common stock were issued to pay services that were included in accounts payable at December 2023 in the amount of $123,860.

 

During the nine months ended September 30, 2024, 1,380,159 shares of common stock were issued to convert $4,000 of a note payable and $1,217 of accrued interest to a related party. The note was converted at a discount of 30% at a average of the lowest closing prices for 30 days prior to January 29, 2024 which produced a loss on debt settlement of $2,236. See Note 3.

 

During the nine months ended September 30, 2024, 1,200,000 shares of common stock were issued to convert $7,613 of a note payable, $2,967 of accrued interest and $1,420 of fees. The note was converted at a flat rate of $0.01. Market value at date of conversion was $0.0176 which produced a loss on debt settlement of $9,120. See Note 5.


FS-13


On July 18, 2024, Quick Capital converted $20,768 of note payable, $176 accrued interest and $1,457 fees for a total of $22,400 into 5,104,831 shares common stock.  The market value on July 18, 2024 was $0.011 or a market value of $56,153 which gave rise to a loss on conversion of $35,209.  

 

On September 9, 2024, Quick Capital converted $4,675 of note payable, $78 accrued interest and $1,457 fees for a total of $6,210 into 1,910,781 shares common stock.  The market value on September 30, 2024 was $0.0073 or a market value of $13,949 which gave rise to a loss on conversion of $7,739.

 

Stock payable at September 30, 2024 consists of 31,739,730 preferred shares and 20,992,665 restricted common shares owed to members of the board of directors and officers for directors’ fees and contract services.  These shares were valued at $818,750 based on the fair value of the Company’s common stock at the date of board authorization. An additional 21,247,612 common shares were owed to as non-related vendors at September 30, 2024 valued at $224,024 based on the fair value of the Company’s common stock at the date of board authorization. 

 

Stock Compensation Plans

 

2020 Stock Plan

 

On September 25, 2020, the Company adopted the Cannabis Sativa 2020 Stock Plan which authorized the Company to utilize common stock to compensate employees, officers, directors, and independent contractors for services provided to the Company. By resolution dated September 25, 2020, the Company authorized up to 1,000,000 shares of common stock to be issued pursuant to the 2020 Stock Plan. This amount was subsequently increased to 2,000,000 shares on January 27, 2021. At September 30, 2024 and December 31, 2023 44,425 shares were available for future issuance.

v3.24.4
7. Commitments and Contingencies
9 Months Ended
Sep. 30, 2024
Notes  
7. Commitments and Contingencies

7. Commitments and Contingencies

 

Litigation.

 

In the ordinary course of business, we may face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject us to litigation. As of September 30, 2024, no claims are outstanding.

v3.24.4
8. Proposed Merger with MJ Harvest, Inc
9 Months Ended
Sep. 30, 2024
Notes  
8. Proposed Merger with MJ Harvest, Inc

8. Proposed Merger with MJ Harvest, Inc.

 

On August 8, 2022, the Company entered into a Merger Agreement (the “Merger Agreement”) with MJ Harvest, Inc. (“MJHI”). Pursuant to the Merger Agreement, MJHI will merge with and into the Company and the Company will be the surviving corporation in the Merger.  The Merger is expected to be consummated once the shareholders of the Company and the shareholders of MJHI approve the Merger which management expects will be completed early in the second quarter of calendar year 2023.  The terms of the Merger Agreement are summarized below:

 

The name of the surviving company in the Merger will be Cannabis Sativa, Inc. 

 

Each share of MJHI common stock outstanding on the effective date of the Merger will be converted into 2.7 shares of CBDS Common Stock. 

 

The Merger is subject to majority approval of the shareholders of both MJHI and CBDS. 

 

The shareholders of MJHI and CBDS will have rights to dissent from the Merger, and, if the notice of dissent is properly given, the dissenting shareholders may be paid fair value for such dissented shares. 

 

The Board of Directors of the surviving company following the Merger is intended to consist of Patrick Bilton, Randy Lanier, Clinton Pyatt, and David Tobias. 

 

The Executive Officers of the Company following the Merger are intended to include Patrick Bilton - Chief Executive Officer, Clinton Pyatt - Chief Operating Officer. 

 

The Merger Agreement includes representations and warranties, covenants, and conditions for MJHI and CBDS as are customary for transactions of this nature. 

 

No brokerage fees are payable in connection with the Merger. 

 

If majority shareholder approval of the merger is not obtained, the Merger will not occur, and the Merger Agreement will be terminated. 

 

All costs and expenses in connection with the Merger transactions will be borne by CBDS, except that MJHI will be responsible for expenses of its own legal counsel and auditing costs. 

 

The merger was withdrawn with the SEC in August 2023. The Company and MJ Harvest are continuing discussions in hopes of completing this transaction. 

v3.24.4
9. Subsequent Events
9 Months Ended
Sep. 30, 2024
Notes  
9. Subsequent Events

9. Subsequent events

 

Entry into a Material Definitive Agreement: 

 

On November 13, 2024, the Board of Directors of Dogecoin Cash, Inc. (formerly Cannabis Sativa, Inc.) authorized the acquisition of 600,000,000 Dogecoin Cash (crypto symbol: DOG) tokens and the entity DogeSPAC, LLC, a Colorado-based entity, from DogeSPAC, LLC, a Puerto Rico company in exchange for 4,500,000 newly issued CBDS preferred shares. This acquisition supports Dogecoin Cash, Inc.’s strategic focus on integrating cryptocurrency solutions into its operational and transactional processes.

 

The Board of Directors authorized a change in the company’s name from Cannabis Sativa, Inc. to Dogecoin Cash, Inc. This change was officially filed and recorded with the state of Nevada on November 13, 2024, as part of the company’s strategic pivot towards digital currency and blockchain applications within its business model.

 

Disclaimer:

Dogecoin Cash, Inc., and the Dogecoin Cash (DOG) token, were inspired by the well-known cryptocurrency Dogecoin; however, Dogecoin Cash, Inc. is not affiliated with, endorsed by, or associated with Dogecoin or its development team.

 

Clarification on Identification:

To prevent any confusion between Dogecoin Cash, Inc. (CBDS), a corporate entity, and Dogecoin Cash (DOG), the cryptocurrency token, each has been assigned a unique CUSIP identifier. Dogecoin Cash, Inc. and its shares are registered with the symbol CBDS, while the Dogecoin Cash (DOG) tokens are identifiable solely within cryptocurrency markets.

 

Change of Auditor

 

On December 9, 2024, the Company’s Board of Directors approved the dismissal of Amitai CPA and engaged Asesoria Global as the Company’s independent registered public accounting firm. This change occurred subsequent to the reporting period ending 9/30/24.

 

There were no disagreements with Amitai CPA on any matter of accounting principles or practices, financial statement disclosures, or auditing scope or procedures during the periods they audited or reviewed.

 

Designation of Preferred Shares

 

To support this transition, Dogecoin Cash, Inc. has declared a special dividend. Common shareholders of record as of November 25, 2024, will receive 1 preferred share for every 1,000 common shares held. This dividend reflects the Board’s commitment to provide value to shareholders in line with the company's new strategic direction.

 

Pursuant to Section 78.1955 of the Nevada Revised Statutes, the undersigned, David Tobias, being the duly authorized Chief Executive Officer of Dogecoin Cash, Inc, a corporation organized and existing under the laws of the State of Nevada does hereby certify that, pursuant to the authority conferred upon the Board of Directors of the Corporation by the Articles of Incorporation, as amended, and pursuant to the provisions of Section 78.1955 of the Nevada Revised Statutes, the Board of Directors, on November 13, duly adopted the following resolution designating a series of 5,000,000 shares of preferred stock as “Series A Preferred Stock”:

 

 

1. Designation and Number of Shares

 

There is hereby designated a series of preferred stock of the Corporation as SERIES A Preferred Stock, consisting of 5,000,000 shares, par value $0.001 per share.

 

2. Dividends

 

Holders of SERIES A Preferred Stock shall be entitled to receive dividends at the rate of 1 common share per annum for each SERIES A Preferred share held on November 25 of each year. Dividends shall be NON CUMULATIVE.

 

3. Liquidation Preference

 

In the event of any liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, the holders of SERIES A Preferred Stock shall be entitled to receive, prior to any distribution to the holders of common stock or any other junior securities, an amount equal to $1 per share, plus any accrued and unpaid dividends.

 

4. Voting Rights

 

The holders of SERIES A Preferred Stock shall have the right to 1 vote for each preferred share held.

 

5. Conversion Rights

 

The holders of SERIES A Preferred Stock shall not have the right to convert their shares into common stock of the Corporation.

 

6. Redemption

 

The Corporation shall have the right to redeem shares of Series A Preferred Stock on or before October 25, 2034, by issuing 10 shares of common stock for each 1 share of Series A Preferred Stock issued and outstanding. Redemption shall be subject to providing prior written notice to the holders of Series A Preferred Stock in accordance with the Corporation’s bylaws, and any other applicable notice requirements, terms, and conditions set forth by the Corporation.

 

v3.24.4
1. Organization and Summary of Significant Accounting Policies: Consolidation, Policy (Policies)
9 Months Ended
Sep. 30, 2024
Policies  
Consolidation, Policy

Principles of Consolidation:

 

The condensed consolidated financial statements include the accounts of Cannabis Sativa, Inc. (the “Company” or “CBDS”), and its wholly-owned subsidiaries and PrestoCorp, a 51% owned subsidiary. All significant inter-company balances have been eliminated in consolidation.

v3.24.4
1. Organization and Summary of Significant Accounting Policies: Substantial Doubt about Going Concern (Policies)
9 Months Ended
Sep. 30, 2024
Policies  
Substantial Doubt about Going Concern

Going Concern:

 

The Company has an accumulated deficit of $82,895,826 at September 30, 2024, which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they are due.

v3.24.4
1. Organization and Summary of Significant Accounting Policies: Use of Estimates, Policy (Policies)
9 Months Ended
Sep. 30, 2024
Policies  
Use of Estimates, Policy

Use of Estimates:

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, and the value attributed to stock-based awards.

v3.24.4
1. Organization and Summary of Significant Accounting Policies: Earnings Per Share, Policy (Policies)
9 Months Ended
Sep. 30, 2024
Policies  
Earnings Per Share, Policy

Net Loss per Share:

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company. Potentially dilutive shares are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. For the nine months ended September 30, 2024 and December 31, 2023 the Company had -0- and 50,000 outstanding warrants, respectively, and -0- shares of convertible preferred stock, respectively, that would be dilutive to future periods net income if converted.

v3.24.4
1. Organization and Summary of Significant Accounting Policies: New Accounting Pronouncements, Policy (Policies)
9 Months Ended
Sep. 30, 2024
Policies  
New Accounting Pronouncements, Policy

Recent Accounting Pronouncement:

 

Accounting Standards Updates Adopted

 

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The update is to address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The update is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and with early adoption permitted. Early adoption of this update had no impact on the Company’s consolidated financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

v3.24.4
2. Intangibles and Goodwill: Schedule of Finite-Lived Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2024
Tables/Schedules  
Schedule of Finite-Lived Intangible Assets

 

September 30,

2024

 

December 31,

2023

CBDS.com website (Cannabis Sativa)

$13,999  

 

$13,999  

Intellectual Property Rights (PrestoCorp)

240,000  

 

240,000  

Patents and Trademarks (KPAL)

1,281,411  

 

1,281,411  

Total Intangibles

1,535,410  

 

1,535,410  

Less: Accumulated Amortization

(1,530,974) 

 

(1,528,151) 

Net Intangible Assets

$4,436  

 

$7,259  

 

v3.24.4
2. Intangibles and Goodwill: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Tables)
9 Months Ended
Sep. 30, 2024
Tables/Schedules  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

 

October 1, 2024 to September 30, 2025

 

$

932 

October 1, 2025 to September 30, 2026

 

 

932 

October 1, 2026 to September 30, 2027

 

 

932 

October 1, 2027 to September 30, 2028

 

 

932 

October 1, 2028 to September 30, 2029

 

 

711

 

v3.24.4
3. Related Party Transactions: Schedule Of Related Party Advance And Notes Payable (Tables)
9 Months Ended
Sep. 30, 2024
Tables/Schedules  
Schedule Of Related Party Advance And Notes Payable

September 30, 2024

Related party payables

 

Accrued interest

 

Total

 

 

David Tobias, CEO & Director

$55,161 

 

$18,047 

 

$73,208 

New Compendium, greater than 10% Shareholder

- 

 

1,906 

 

1,906 

Stock payable – Directors & Officers

818,750 

 

- 

 

818,750 

Cathy Carroll, Director

151,750 

 

986 

 

152,736 

Totals

$1,025,661 

 

$20,939 

 

$1,046,600 

 

 

December 31, 2023

Related party payables

 

Accrued interest

 

Total

 

 

David Tobias, CEO & Director

$47,920 

 

$13,779 

 

$61,699 

New Compendium, greater than 10% Shareholder

- 

 

1,906 

 

1,906 

Cathy Carroll, Director

109,250 

 

986 

 

110,236 

Stock payable – Directors & Officers

606,250 

 

- 

 

606,250 

Other Affiliates

4,000 

 

1,200 

 

5,200 

Totals

$767,420 

 

$17,871 

 

$785,291 

 

v3.24.4
3. Related Party Transactions: Schedule of Related Party Transactions (Tables)
9 Months Ended
Sep. 30, 2024
Tables/Schedules  
Schedule of Related Party Transactions

Three Months Ended

September 30, 2024

Three Months Ended

September 30, 2023

Nine Months Ended

September 30, 2024

Nine Months Ended

September 30, 2023

Directors fees

$- 

$11,875 

$23,750 

$35,625 

Outside services

59,375 

59,375 

178,125 

178,125 

Management fee

2,500 

32,051 

29,787 

76,151 

Payroll expenses

- 

- 

38,896 

- 

 

v3.24.4
1. Organization and Summary of Significant Accounting Policies: Substantial Doubt about Going Concern (Details) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Details    
Accumulated deficit $ (82,895,826) $ (82,083,492)
v3.24.4
2. Intangibles and Goodwill: Schedule of Finite-Lived Intangible Assets (Details) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Total Intangibles $ 1,535,410 $ 1,535,410
Less: Accumulated Amortization (1,530,974) (1,528,151)
Intangible assets, net 4,436 7,259
Internet Domain Names | Cannabis Sativa    
Total Intangibles 13,999 13,999
Intellectual Property | Prestocorp    
Total Intangibles 240,000 240,000
Patents And Trademarks | KPAL    
Total Intangibles $ 1,281,411 $ 1,281,411
v3.24.4
2. Intangibles and Goodwill (Details) - USD ($)
3 Months Ended 9 Months Ended
Aug. 01, 2017
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Amortization of Intangible Assets   $ 233 $ 37,921 $ 3,028 $ 113,763  
Goodwill   1,775,811   1,775,811   $ 1,775,811
Prestocorp            
Goodwill, Impairment Loss $ 3,010,202          
Goodwill, Impaired, Accumulated Impairment Loss   1,234,391   1,234,391   1,234,391
Goodwill   $ 1,775,811   $ 1,775,811   $ 1,775,811
v3.24.4
2. Intangibles and Goodwill: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details)
Sep. 30, 2024
USD ($)
Details  
Finite-Lived Intangible Asset, Expected Amortization, Year One $ 932
Finite-Lived Intangible Asset, Expected Amortization, Year Two 932
Finite-Lived Intangible Asset, Expected Amortization, Year Three 932
Finite-Lived Intangible Asset, Expected Amortization, Year Four 932
Finite-Lived Intangible Asset, Expected Amortization, Year Five $ 711
v3.24.4
3. Related Party Transactions (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Proceeds from related parties notes payable, net     $ 7,240 $ 26,719  
Note payable issued for services     42,500 70,000  
Notes payable to related parties $ 206,911   206,911   $ 161,170
Interest Expense, Debt 2,640 $ 1,945 12,786 13,761  
Advances to related party $ 76,305   $ 76,305   75,054
Related Party Note Payable          
Note payable issued for services       $ 160,685  
Debt Instrument, Interest Rate, Stated Percentage 5.00% 8.00% 5.00% 8.00%  
Interest Expense, Debt $ 586 $ 4,559 $ 2,026 $ 16,374  
Chief Executive Officer and Director          
Proceeds from related parties notes payable, net     $ 7,240 $ 22,721  
Debt Instrument, Interest Rate During Period     5.00%    
Debt Instrument, Maturity Date     Dec. 31, 2024    
Notes Payable 55,160   $ 55,160   59,420
Director          
Debt Instrument, Interest Rate During Period       5.00%  
Note payable issued for services       $ 42,500  
Notes payable to related parties $ 151,750   151,750   109,250
Long-Term Debt, Average Amount Outstanding     $ 4,000    
Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate 5.00%   5.00%    
Advances to related party $ 0   $ 0   1,250
MJ Harvest, Inc.          
Advances to related party $ 75,054   $ 75,054   $ 75,054
v3.24.4
3. Related Party Transactions: Schedule Of Related Party Advance And Notes Payable (Details) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Related Party Payables $ 1,025,661 $ 767,420
Accrued Interest Related Parties, Current And Noncurrent 20,939 17,871
Related Parties, Notes Payable and Accrued Interest 1,046,600 785,291
Chief Executive Officer and Director    
Related Party Payables 55,161 47,920
Accrued Interest Related Parties, Current And Noncurrent 18,047 13,779
Related Parties, Notes Payable and Accrued Interest 73,208 61,699
New Compendium (Shareholder)    
Related Party Payables 0 0
Accrued Interest Related Parties, Current And Noncurrent 1,906 1,906
Related Parties, Notes Payable and Accrued Interest 1,906 1,906
Stock payable    
Related Party Payables 818,750 606,250
Accrued Interest Related Parties, Current And Noncurrent 0 0
Related Parties, Notes Payable and Accrued Interest 818,750 606,250
Director    
Related Party Payables 151,750 109,250
Accrued Interest Related Parties, Current And Noncurrent 986 986
Related Parties, Notes Payable and Accrued Interest $ 152,736 110,236
Other Affiliates    
Related Party Payables   4,000
Accrued Interest Related Parties, Current And Noncurrent   1,200
Related Parties, Notes Payable and Accrued Interest   $ 5,200
v3.24.4
3. Related Party Transactions: Schedule of Related Party Transactions (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Details        
Directors fees $ 0 $ 11,875 $ 23,750 $ 35,625
Outside services 59,375 59,375 178,125 178,125
Management fee 2,500 32,051 29,787 76,151
Payroll expenses $ 0 $ 0 $ 38,896 $ 0
v3.24.4
4. Investments (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2021
Dec. 31, 2023
Loss on return of investment securities   $ 0 $ 0 $ 33,000 $ 155,735    
REFG              
Investment Owned, Balance, Shares   0   0     0
Investment Sold $ 9,041            
Loss on return of investment securities $ 155,735            
CBDG              
Sale of Stock, Price Per Share           $ 0.2  
Proceeds from Issuance or Sale of Equity           $ 600,000  
Percentage Of Voting Share           15.00%  
Investments, Fair Value Disclosure   $ 18,000   $ 18,000     $ 66,000
Gain (Loss) on Investments   $ (7,500) $ 28,800 $ (15,000) $ (185,083)    
CBDG | Common Stock              
Stock Repurchased During Period, Shares           1,500,000  
CBDG | Preferred Stock              
Stock Repurchased During Period, Shares           1,500,000  
v3.24.4
5. Convertible Notes Payable (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 09, 2024
Jul. 18, 2024
Jun. 26, 2024
May 22, 2024
Jan. 15, 2024
Sep. 18, 2023
Aug. 16, 2023
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 19, 2023
Jan. 31, 2023
Fair value of convertible component in convertible loans $ 174,490               $ 174,490       $ 174,490   $ 0    
Shares issued in consideration of convertible notes payable                 70,101 $ 28,573 $ 195,277 $ 39,000 91,221 $ 160,236      
(Gain) loss on debt settlement                 44,406   88,591   52,182 99,118      
Proceeds from convertible note payable                         30,000 33,056      
Interest Expense, Debt                 2,640   $ 1,945   12,786 $ 13,761      
Quick Capital, LLC                                  
Notes Payable       $ 7,613                          
Debt Instrument, Increase, Accrued Interest                 2,967                
Conversion Fees                 1,420                
(Gain) loss on debt settlement                 9,120                
2023 Agreement | Quick Capital, LLC                                  
Debt Instrument, Face Amount             $ 33,055                    
Notes Payable   $ 4,675 $ 20,768 7,613                          
Fair value of convertible component in convertible loans 103               103       103        
Debt Instrument, Interest Rate During Period             12.00%                    
Debt Instrument, Increase, Accrued Interest   78 176 2,967                          
Conversion Fees   1,457 1,457 1,420                          
Shares issued in consideration of convertible notes payable   $ 6,210 $ 22,400 $ 12,000                          
Shares, Outstanding   1,910,781 5,104,831 1,200,000                          
(Gain) loss on debt settlement 7,739 $ 35,209   $ 9,120                          
2023 Agreement | Colonial Stock Transfer Company, Inc.                                  
Debt Instrument, Face Amount               $ 11,020                  
Agreement Payment, Description               If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 25% discount                  
Debt Instrument, Interest Rate During Period               10.00%                  
2024 Agreement | Quick Capital, LLC                                  
Debt Instrument, Face Amount         $ 33,333                        
Fair value of convertible component in convertible loans 0               0       0        
(Gain) loss on debt settlement         3,333                        
Proceeds from convertible note payable         25,000                        
Payments of Loan Costs         $ 5,000                        
Director                                  
Debt Instrument, Interest Rate During Period                           5.00%      
(Gain) loss on debt settlement                 2,236                
Director | 2023 Agreement                                  
Debt Instrument, Face Amount                                 $ 72,262
Compensation and Benefits Trust                                 $ 25,000
Notes Payable                             $ 85,762 $ 11,500  
Stock Issued During Period, Shares, Conversion of Convertible Securities                             6,700,000    
Stock Issued During Period, Value, Conversion of Convertible Securities                             $ 36,800    
Conversion Gains And Losses                             $ 25,300    
Agreement Payment, Description                             If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 30% discount    
Fair value of convertible component in convertible loans 27,083               27,083       27,083        
Director | 2024 Agreement                                  
Debt Instrument, Face Amount           $ 75,000                      
Agreement Payment, Description           . If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 30% discount                      
Fair value of convertible component in convertible loans $ 147,304               $ 147,304       $ 147,304        
Debt Instrument, Interest Rate During Period           5.00%                      
v3.24.4
6. Stockholders' Equity (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 09, 2024
Jul. 18, 2024
Jun. 26, 2024
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Mar. 31, 2024
Dec. 31, 2023
Dec. 19, 2023
Dec. 31, 2022
Jan. 27, 2021
Sep. 25, 2020
Common Stock, Shares Authorized 495,000,000       495,000,000         495,000,000     495,000,000        
Note payable issued for services                   $ 42,500 $ 70,000            
Stock issued for services             $ 88,200 $ 88,200   0 88,200            
Common stock issued for services in accounts payable         $ 123,860 $ 123,860       123,860 0            
(Gain) loss on debt settlement         44,406   88,591     52,182 99,118            
Shares issued in consideration of convertible notes payable         $ 70,101 $ 28,573 $ 195,277 $ 39,000   91,221 160,236            
Stock payable for services                   $ 390,631 319,701            
Additional Common Shares Owed To Various Non-Related Vendors, Shares                   21,247,612              
Additional Common Shares Owed To Various Non-Related Vendors, Value                   $ 224,024              
Employee Stock Ownership Plan (ESOP), Number of Allocated Shares                               2,000,000 1,000,000
Common Stock, Capital Shares Reserved for Future Issuance 44,425       44,425         44,425     44,425        
Quick Capital, LLC                                  
(Gain) loss on debt settlement         $ 9,120                        
Notes Payable       $ 7,613                          
Debt Instrument, Increase, Accrued Interest         2,967                        
Conversion Fees         1,420                        
Quick Capital, LLC | 2023 Agreement                                  
(Gain) loss on debt settlement $ 7,739 $ 35,209   9,120                          
Notes Payable   4,675 $ 20,768 7,613                          
Debt Instrument, Increase, Accrued Interest   78 176 2,967                          
Conversion Fees   1,457 1,457 1,420                          
Shares issued in consideration of convertible notes payable   $ 6,210 $ 22,400 $ 12,000                          
Shares, Outstanding   1,910,781 5,104,831 1,200,000                          
Director                                  
Note payable issued for services                     42,500            
Long-Term Debt, Average Amount Outstanding                   $ 4,000              
(Gain) loss on debt settlement         $ 2,236                        
Director | 2023 Agreement                                  
Notes Payable                         $ 85,762 $ 11,500      
Related Party Note Payable                                  
Note payable issued for services                     $ 160,685            
Common Stock                                  
Common stock issued - note payable conversion         7,015,612 2,580,159 9,778,937 1,711,397 320,513 1,380,159              
Stock Issued During Period, Shares, Issued for Services             2,450,000 2,450,000                  
Stock issued for services               $ 2,450                  
Common stock issued for services in accounts payable - shares         11,620,476 11,620,476                      
Common stock issued for services in accounts payable           $ 11,620                      
Shares issued in consideration of convertible notes payable         $ 7,015 $ 2,580 $ 9,779 $ 1,711                  
Shares, Outstanding 110,030,284       110,030,284 103,014,672 59,827,210 50,048,273 45,886,876 110,030,284 59,827,210 88,814,037 88,814,037   45,566,363    
Stock Payable, Shares                   20,992,665              
Stock payable for services                   $ 818,750              
Common Stock | Related Party Note Payable                                  
Common stock issued - note payable conversion                     11,810,847            
Preferred Stock                                  
Stock Payable, Shares                   31,739,730              

Cannabis Sativa (QB) (USOTC:CBDS)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Cannabis Sativa (QB) Charts.
Cannabis Sativa (QB) (USOTC:CBDS)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Cannabis Sativa (QB) Charts.